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HN-infected macrophages are frequently present in semen of untreated HIV-
infected men. After intercourse, there is evidence that these cells infiltrate from the 
vaginal epithelial surface into the mucosa (apical to basal infiltration) and transmit HN 
to a new host. Since women with cervicovaginal inflammation are at an increased risk of 
acquiring HN, we hypothesized that epithelial inflammation enhances cell-associated 
HN transmission via increased seminal leukocyte infiltration into the vaginal mucosa. In 
order to investigate this mechanism, we utilized an in vitro reconstructed human vaginal 
epithelium that is structurally similar to normal human mucosa. We have used confocal 
microscopy to characterize the kinetics of apical to basal infiltration of Phorbol-12-
myristate-13-acetate activated U937 macrophages as well as non-infected and HIV-
infected primary monocyte-derived macrophages (MOMs) through this vaginal mucosal 
v 
model. Within two hours of placement on the apical side of the epithelium, both non-
infected and HIV -infected macrophages were abundant within the uppermost cell layers 
(stratum corneum) and a subpopulation of these cells were observed to have infiltrated 
through intact epithelial junctions to reach depths ranging from 50-200flm. Infiltration of 
both non-infected and infected cells was significantly enhanced when the Epivaginal 
tissues were pre-treated with TNF-alpha, an important pro-inflammatory cytokine. 
Through microarray analysis and Enzyme-linked immunosorbent assay (ELISA), we 
demonstrated that exposure to TNF-alpha upregulated transcription and/or expression of 
several chemotactic factors and matrix metalloproteases, the presence of which may have 
contributed to increased leukocyte infiltration into inflamed epithelium. Additionally, 
TNF-alpha treatment resulted in a dramatic increase in epithelial expression of 
intercellular adhesion molecule 1 (ICAM-1). 
These data provide evidence that HIV -infected macro phages can infiltrate into the 
normal human vaginal epithelium from the vaginal lumen after intercourse, and that 
cervicovaginal inflammation enhances infiltration. These studies provide further insight 
into potential mechanisms of cell-associated HIV transmission and suggest that strategies 
to inhibit vaginal inflammation, and/or block leukocyte attachment and infiltration may 
be a relevant approach to prevent HIV transmission. 
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Introduction 
The year 1980 heralded a senes of mysterious outbreaks of opportunistic 
infections in otherwise healthy gay men and hemophiliacs across the United States. This 
group of diseases was officially coined Acquired Immunodeficiency Syndrome (AIDS), 
although the causative agent, Human Immunodeficiency Virus Type 1 (HIV -1 ), was not 
discovered until 1983.1 In the thirty years since its discovery HIV has infected 60 million 
people and more than 30 million have died from the disease? Despite the most fervent 
efforts of the scientific community, there is still no vaccine or cure. 
HIV is primarily transmitted during unprotected sexual intercourse, gestation and 
vaginal delivery, breast feeding, and intravenous drug use (Table 1).3 The first few weeks 
of infection, the acute phase, is classically accompanied by flu-like symptoms including 
fever, chills, body-aches and lymphadenopathy. This is concordant with high viral load, 
decreased CD4+ T cell count and increased infectivity.4 A large percentage of new 
infections are acquired from acute phase HIV+ partners, as the transmitting individual is 
unlikely to know they his or her HIV status but is significantly more infectious due to 
high peripheral blood and genital viral loads. 5 A few weeks after the initial surge of viral 
replication, viral load is stabilized at low levels and patients experience fewer clinical 
symptoms. This is termed 'clinical latency' and can last anywhere from a few months to a 
decade or more before the patient progresses to AIDS, which is defined by a CD4+ T cell 
count below 200 cells/ Ill or infection with an AIDS defining opportunistic illness.2 Death 
does not result from AIDS itself, but rather from complications associated with the 
depletion of CD4+ T cells, immunosuppression and secondary disease. Highly active 
antiretroviral therapy (HAART) significantly slows progression to AIDS as well as 
increases the lifespan of AIDS patients. Only 5-15% of the HIV+ population are able to 
suppress viral replication in the absence oftherapy.6 
HIV continues to spread, particularly amongst young women m sub-Saharan 
Africa.2 Per unprotected heterosexual exposure, females are twice as likely to contract 
HIV than their male partners. 7'8 Although only 1 in 1000 unprotected heterosexual 
exposures will lead to HIV infection in women on average, there are several risk factors 
that augment HIV transmission efficiency.9 Women in resource poor settings are often 
unable to negotiate condom use and are more likely to be victims of sexual violence. 10 
African women also commonly use vaginal drying products or soaps before sexual 
contact, increasing the incidence of microabrasions incurred during intercourse and over 
time, and altering the protective vaginal flora. 11 Specifically, the loss of protective 
Lactobacillus species causes a condition known as bacterial vaginosis (BV) and is a 
major risk factor for HIV acquisition. 11 •12 Most notably the presence of cervicovaginal 
inflammation, as would occur with sexually transmitted infections (STis) or the use of 
irritating chemical products, is well described to enhance HIV transmission (Table 2). 13•14 
The high prevalence of STis and BV in sub-Saharan Africa has been cited by many as a 
major contributor to continued spread of the epidemic. 15 
Much research has gone into understanding how genital inflammation enhances 
HIV infection. Some of these mechanisms are very clear; for example, ulcerating STis 
such as herpes simplex virus-2 (HSV -2) create portals by which infectious material is 
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able to bypass the mucosal barrier and access CD4+ target cells. Individuals that are co-
infected with HSV -2 are at a greater risk of acquiring HIV than those with non-ulcerating 
infections. (Table 2) However, what is the mechanism by which genital inflammation 
enhances HIV transmission in the absence of open wounds? One possible explanation is 
that pro-inflammatory mediators that act through nuclear factor kappa B signaling 
pathways can enhance HIV replication in mucosal leukocytes. Inflammation also induces 
epithelial secretion of chemokines that function to attract leukocytes from the periphery 
to the vaginal epithelium, effectively increasing the concentration of potential HIV target 
cells at the site of exposure. At other mucosal sites, it is known that leukocytic infiltration 
is further facilitated by inflammation-induced remodeling of epithelial junctions and 
enhanced expression of leukocyte adhesion molecules. It is our hypothesis that these 
mechanisms also function to facilitate transfer of HIV across the epithelial barrier. After 
intercourse with an HIV infected male, infectious material is deposited in the vaginal 
lumen in two forms: free virions (cell-free HIV) and infected leukocytes (cell-associated 
HIV). It is very possible that these foreign, HIV -harboring immune cells from semen are 
also attracted into the inflamed epithelium by the same mechanisms that attract host 
leukocytes from the bloodstream. The apical to basal infiltration of infected cells would 
effectively transport HIV across the epithelial barrier, bringing the virus in closer 
proximity to target cells and protecting it from anti-HIV antibodies in semen and innate 
anti-microbial factors in the vaginal lumen. A better understanding of this pathway could 
lead to the discovery of effective, targeted strategies to prevent new infections. 
3 
Exposure route Risk per 10,000 R~ference 
Blood Transfusion 9,000 Donegan et al. 
Needle Sharing 67 Kaplan et al. 
Receptive penile-vaginal 10 Euro. Study Group, 
intercourse Varghese et. a! 
Insertive penile-vaginal 5 Euro. Study Group, 
intercourse Varghese et. a! 
Receptive Anal 50 Euro. Study Group, 
Intercourse Varghese et. al 
Insertive Anal 6.5 Euro. Study Group, 
Intercourse Varghese et. al 
Table adapted from original created by the U.S. Centers for Disease Control and 
Prevention, 2005. 
Table 1: Estimated Risk of HIV Infection by Exposure Route. Direct contact with 
blood from an HIV infected individual (needle sharing and transfusions) carries the 
greatest risk of transmission. Although sexual transmission of HIV carries less risk per 
incident, the vast majority of infections are spread through contact with mucus 
membranes. 80% of all HIV infections worldwide occur via heterosexual intercourse. 
The disease statistics are different in developed countries; according to the United 
States Centers for Disease Control (CDC), gay men make up 2% of the total US 
population but accounted for 60% of all new HIV infections in 2009. 
Enhanced 
Population susceptibility to HIV 
Selected references Region studied Size (aOR) 
GC (4.8), CT (3.6), 
Laga et al 1993 Zaire FSW 431 Trich (1.9) 
Dominguez et al GC (23 .5), CT (10.7), 
1996 USA anti-natal 386 4.7 Trich, Syphilis (8.6) 
Taha et al1998 Malawi anti-natal 1169 GC (4.3), BV (3 .7) 
Kapinga et al 2002 Tanzania bar/hotel workers 312 BV (2.4) BY, HSV (2.5) 
Reynolds et al 2006 India STI clinic 2324 Syphilis (4.4) 
Myer et al. 2006 South Africa cancer screening 5510 BV (2.01) 
Table 2: Sexually Transmitted Infections Enhance Susceptibility to HIV. Common 
STI's: Neisseria gonorrhoeae (GC), Chlamydia trachomatis (CT), Candida 
albicans (CA), herpes simplex virus 2 (HSV -2) and Treponema pallidum (Syphilis) 
are associated with an increased risk of HIV acquisition. In addition, bacterial 
vaginosis (BV) is also a risk factor for infection. BV is a condition caused by 
colonization with abnormal vaginal flora that results in increased vaginal pH. The 
high prevalence of STis and BV in sub-Saharan Africa has been cited by many as a 
major contributor to continued spread of the HIV epidemic. 
5 
Background 
Section 1: HIV Virology 
HIV-1 is a member of the genus Lentivirus and family Retroviridae. 16 It is a 
single stranded, positive sense RNA lentivirus that encodes 9 genes and 14 viral proteins 
(Table 3). As seen in Figure 1, the virion is encapsulated by a host cell-derived lipid 
bilayer studded with viral envelope glycoproteins gp41 (transmembrane) and gp120 
(surface) that complex to form trimers. The internal structure of the virion is composed of 
Gag proteins matrix (p17), capsid (p24), nucleocapsid (p7) and p6. The cone shaped 
capsid, composed of p24 protein, contains 2 strands of viral RNA and the enzymes 
. . d 16 reverse transcnptase, mtegrase an protease. 
The infection of a new cell proceeds as follows (Figure 2): exposed gp120 trirners 
on the surface of the virion specifically bind the CD4 surface receptor present on 
macrophages, some T cells and dendritic cells (DCs). This interaction induces a 
conformational change in gp120 that exposes the chemokine co-receptor binding site 
(most commonly CCR5 or CXCR4). A second conformational change allows gp41-
mediated viral envelope fusion with the host cell membrane and entry of the HIV capsid 
into the cell. After entry and uncoating, reverse transcriptase mediates both the reverse 
transcription of viral RNA into DNA as well as the degradation of the viral template 
RNA. This allows a second strand of complementary DNA to be synthesized to yield 
circular double stranded viral DNA.16 HIV reverse transcription is extremely error prone, 
resulting in an unusually high rate of mutation (1.4 x 10- 5 per round of replication). 17 
The viral DNA complexes with viral integrase and several host cellular proteins and is 
6 
transported to the nucleus via the host cell microtubule network, a process potentially 
facilitated by the viral protein Vpr. 18 Once inside the nucleus, integrase facilitates the 
integration ofHIV DNA into active areas of transcription in the host cell genome. This is 
now referred to as the mv provirus. 16 
Transcription of the provirus proceeds similarly to the transcription of any other 
host gene. It is regulated by the binding of transcription factors to the 5' long-terminal 
repeat (LTR) segment of the HIV genome, which serves as the promoter region. The LTR 
contains binding sites for several host transcription factors involved in the immune 
response including NF-KB, AP-1, Sp 1 and NF-AT and as such transcription is strongly 
enhanced by T cell or macrophage activation. 16' 19 A small number of short, initial 
transcripts are produced that encode the HIV proteins Rev, Nef and Tat. Tat is an 
elongation factor; once it has been synthesized, Tat binds the initial viral mRNA 
transcript (a hairpin loop structure called TAR) and recruits the transcription elongation 
factor (P-TEFb) complex to the site of transcription, enabling the efficient synthesis of 
full-length mRNA transcripts.20 Rev is responsible for exporting viral mRNA into the 
cytoplasm before it can be spliced by host cell machinery in the nucleus, ensuring 
translation of viral structural proteins?1'22 Capsid and envelope glycoproteins are first 
produced as long precursor proteins that are later cleaved by host or viral enzymes. 
(Table 2) After synthesis, Gag associates with the plasma membrane and autonomously 
mediates assembly of the new virion. Viral RNA and Env glycoproteins are also targeted 
to the membrane and incorporated into the virion along with structural proteins and 
enzymes. Like other primate lentiviruses, HIV assembles at and buds from the cell 
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membrane, and is wrapped in a gpl20/41 studded host cell membrane that shields it from 
the extracellular environment.23 The immature virion is then pinched off and released. 
Inside the immature virion, viral protease mediates several Gag cleavage events after 
which the mature and infectious virion is formed. The ring shaped appearance of the 
capsid in the immature virion is easily distinguished from the dense cone-shaped capsid 
of mature virion by electron microscopy_24 
8 
Gene Gene Products and Function 
KJroup-specific antigen. Encodes precursor p55 is processed by viral 
!Protease to capsid proteins p17(matrix), p24 ®psid), p7(nucleo£apsid) and 
gag p6 
~merase. Encodes viral enzymes protease, reverse transcriptase and 
;pol integrase 
~elope. Precursor gp160 is processed to gp41 (transmembrane) and 
gp120 (surface), which are complexed on the cell surface in trimers. Gp120 
~nv [binds CD4 and co-receptors. 
~rans£!ctivator of transcription. Required HIV accessory protein, binds 
If AR RNA element to activate transcription initiation and elongation from 
at heLTR. 
~lator of yiral expression. Required HIV accessory protein, binds Rev 
esponsive element (RRE) on viral mRNA to promote nuclear export 
rev before it can be spliced by host machinery. 
Y:iral infectivity factor. Prevents the action of host cell antiviral protein 
vif APOBEC-3G. 
~iral nrotein R. Interacts with p6 and localized to nucleus, proposed 
vpr functions include: cell cycle arrest, promotes infection ofmacrophages. 
~iral nrotein U. Degradation of CD4 in endoplasmic reticulum, enhances 
vpu virion release from the membrane. 
~ative regulatory factor. Promotes immune evasion by decreasing CD4 
and MHC class I expression at cell membrane. Required for in vivo but not 
nef in vitro HIV infectivity. 
Adapted from: HIV Sequence Database: Landmarks ofthe HIV genome. 
http://www.hiv.lanl.gov 
Table 3: HIV encoded gene products and assigned functions in vivo. HIV encodes 9 
genes and 14 viral proteins with various functions in the H1V lifecycle and 
pathogenesis. 
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lipid membrane 
~ 
0' 
Reverse 
transcri ptase 
Figure I: HIV Structure. The HIV virion is similar to that of other retroviruses. It 
is encapsulated by host cell-derived lipid membrane studded with viral 
glycoprotein gp41/gp120 trimers, which mediate binding to the CD4 receptor on 
a new target ceiL Matrix proteins provide structural support. The cone shaped 
capsid, composed of p24 protein, contains 2 strands of viral RNA and the 
enzymes reverse transcriptase, integrase and viral protease. 
10 
/' 
1. HIV gpl20 CD4 
engages host CD4 
6. Viral protease mediates 
Gag cleavage events, forming 
the mature and infections 
virion. 
0 
0013 13 
o( t?,lp 
2. HIV gp41 engages 
host co-receptor 
CXCR4 or CCRS, 
followed by 
membrane fusion and 
entry of the capsid 
0 - ( 
~3 . Viral DNA 
• ~ is synthesized 
~ by reverse 
- ...,. r- transcription 
11 
and 
' transported 
\into the 
nucleus 
v _. I 
' ~ / ;-.. -t ~New viral DNA 
5. HIV RNA and proteins 
assemble at the membrane to 
form the immature virions, 
which is pinched off into the 
extracellular environment 
Figure 2: HIV Life Cycle. Exposed gp 120 trimers on the surface of the virion 
specifically bind the CD4 surface receptor present on macrophages and T cells. 
This interaction induces a conformational change in gp120 that exposes the 
chemokine co-receptor binding site (most commonly CCR5 or CXCR4). A 
second conformational change allows gp41-mediated viral envelope fusion and 
entry of the HIV capsid into the cell. After entry and uncoating, reverse 
transcriptase mediates transcription of viral RNA into DNA and is shuttled into 
the nucleus via the host cell microtubule network. Viral integrase facilitates the 
insertion of the HIV genome into host DNA and from there, transcription of the 
provirus proceeds similarly to the transcription of any other host gene. mRNA 
and full length RNA are transported out of the nucleus, viral proteins are made 
in the cytoplasm and assembled at the plasma membrane. The immature virion, 
which contains RNA and viral enzymes, is pinched off and released into the 
extracellular environment. Lastly, protease-mediated Gag cleavage events give 
rise to a mature and infectious virion. 
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Section 1.1: Viral Subtypes 
HIV is a genetically diverse pathogen. The two known species ofHIV, HIV-1 and 
HIV -2, arose from different strains of simian immunodeficiency virus (SIV), SIV cpz and 
SIV sm, respectively.25 Of these, HIV-2 is considerably less pathogenic and is confined to 
West Africa. 16•25 As HIV -1 is the predominant infection worldwide, it is the major focus 
of scientific investigation. As illustrated in Figure 3, HIV -1 can be categorized into 4 
groups: major group (M), outlier group (0), and two new groups N and P. 16 Nine clades 
(A, B, C, D, F, G, H, J and K) have been identified within the M group, the most 
widespread cause of infection. Hybrid viruses emerge from persons infected with more 
than one clade and those that survive to be transmitted to a new host are termed 
'circulating recombinant forms', or CRF's.25 The most common of these is CRF AlE, 
which is found in southeast Asia. Clade B infections are predominant in developed 
countries in the Americas, Europe and Australia while clade A and C subtypes are much 
more common in sub-Saharan Africa.26 
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Figure 3: IDV Phylogenetic Tree 
HIV-1 HIV-2 
Group M GroupN Group 0 Group P 
I 
A B c D E F G H J K CRFs 
Figure 3: HIV phylogenetic tree. The two known species ofHIV, IDV-1 and HIV-2, 
arose from different strains of simian immunodeficiency virus (SIV), SIV cpz and 
SIV sm, respectively. HIV -1 is the most common cause of infection worldwide and 
can be divided into 4 groups: M, N, 0 and P. Group M can further be broken down 
into 9 major clades as well as circulating recombinant forms (CRFs) that are 
chimeras of other known clades. 
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Section 1.2: Tropism and Founder Viruses 
In 1987, Koyanagi et al isolated two distinct but related HIV strains from the 
same patient.27 Both were capable of productively infecting peripheral blood 
mononuclear cells (T cell-tropic), but only ·one was capable of efficiently infecting 
macrophages (M-tropic). Several years later, another group published that M-tropic 
strains were commonly found in asymptomatic patients whereas viruses capable of 
infecting both macrophages and T cells were associated with severe immunodeficiency 
and progression to AIDS?8 It was not until 1996 that co-receptors CCR5 and CXCR4 
were discovered29 and it became clear that M-tropic strains utilized CCR5 to gain entry 
into cells whereas T cell tropic strains were reliant upon CXCR4, giving rise to the 
current terminology R5, X4 and dual-tropic strains for viruses that can use either 
receptor. 
It is now known that the vast majority of transmitted (founder) strains are R5 
tropic, even in cases where the transmitting individual is infected with predominantly X4 
tropic viruses.30 The co-receptor switch during the course of infection occurs in an 
estimated 40% ofHIV patients and more frequently in subtype Band D infections.30 To 
date, it is unclear if switching from R5 to X4 co-receptor usage is a byproduct of 
accelerated disease progression or causes it. 
In comparison to the vast number of viral mutants that can exist in a host, it is 
surprising that many have shown that only one, or at most two to five, variants are 
transmitted at a time. In one study, Keele et al. found that a single virus was responsible 
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for 76% oftransmissions.31 Often, the transmitting strain or strains(s) is a minor variant 
in the transmitting partner implying that there are factors that endow some quasispecies 
with properties that allow for enhanced transmission. As discussed previously, the 
preferentially transmitted virus almost universally utilizes the CCR5 co-receptor. In 
addition, founder virus envelopes have been found to have shorter exposed variable loops 
and be less glycosylated, 32•33 a feature that likely increases exposure of the CD4 binding 
domain.34 However, this region is also highly immunogenic and has been shown to be 
rapidly neutralized by antibodies from the transmitting host. 35 Thus suggests that viral 
envelope mutations that allow evasion form the host immune system may come with 
transmission fitness cost.34 Founder viruses have been additionally found to be 
genetically closer to the ancestral strain that the pool of circulating viruses in the 
transmitter, and as such selection is thought to create a genetic bottleneck that essentially 
h b d h f . 1 d" . . . 313637 resets t e rea t o vrra Iversity at transmission. · · 
One group has reported that there is a gender differences in the number of strains 
transmitted at the initial infection event. In one study by Long et al., 63% of Kenyan 
women (20 out of32) were infected with more than one founder strain where as all ofthe 
men studied (10 out of 10) were infected by a single virus.38 However, the authors report 
that prevalence of STis in this cohort was high and as previously mentioned, genital 
inflammation enhances HN transmission. A statistical analysis by Abrahams et al. 
suggests that infection by multiple, independent cell-free viruses is statistically unlikely, 
but that transmission of multiple variants via a single infectious unit, such as may occur 
in cell-associated HIV transmission, may explain this discrepancy.39 
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Section 2: Mechanisms of HIV Transmission 
HIV transmission occurs most commonly through mucosal surfaces such as the 
infant oraVgastrointestinal epithelium, rectal epithelium as well as the epithelium that 
lines both the male and female reproductive tracts. In women, the upper genital tract 
(endocervix and uterus) is distinct from the lower genital mucosa (ectocervix and vagina) 
in terms of epithelial structure (Figure 4), resident leukocyte populations, mucus 
composition, microbiota and secretion of innate anti-microbial compounds (Section 3). 
HIV infection of resident immune cells has been demonstrated in all of these tissues, but 
the relative frequency of infection at these sites is still unclear.9 Although we recognize 
that the upper genital tract may also be an important portal for HIV infection, the studies 
presented here are focused on elucidating the mechanisms of HIV transfer across the 
stratified epithelium ofthe lower genital tract. 
Local target cells could be infected by free virions (cell-free HIV) and/or through 
contact with an infected seminal leukocyte (cell-associated HIV, or CA-HIV). Since there 
are few mucosal leukocytes that normally reside near the epithelial surface, viral 
penetration of the upper layers of the epithelial barrier may be required to establish 
infection. The potential mechanisms by which HIV crosses the epithelial barrier and 
infects target cells in the mucosa are outlined in Sections 2.1-2.3. 
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Endocervix and 
Uterus (simple 
columnar 
epithelium 
Ectocervix and Vagina 
(stratified squamous 
epithelium) 
Figure 4: Anatomy of the Female Reproductive Tract. There are 4 major 
proposed sites of HN infection in the female genital tract: vagina, ectocervix, 
endocervix and uterus. The epithelium that lines the lower female reproductive 
tract (vagina and ectocervix) is stratified squamous in construction and is 20-30 
cell layers deep. 
18 
Section 2.1: Infection of Mucosal HIV Target Cells: Dendritic Cells, CD4+ T cells and 
Macrophages 
Under non-inflammatory conditions, the majority of intraepithelial leukocytes in 
the stratified squamous epithelium of the ectocervix and vagina are of dendritic cell (DC) 
origin (CD1a+).40 Although few in number, DCs have been visualized at the epithelial 
surface in an in vitro human vaginal epithelial reconstruction model,41 and insert 
pseudopodia to sample bacterial antigens in the gastrointestinal lumen.42 For these 
reasons, many have hypothesized that dendritic cells are the first to come in contact with 
HIV in the vaginal lumen.43 DCs are a heterogeneous population of cells that have 
varying functions dependent upon the tissue of origin. In the ectocervical and vaginal 
mucosa, CDla+, DC-SIGN+ dendritic cells are found almost exclusively in the lamina 
propria while Langerhans cells (LCs), a specialized subset of immature DCs, reside in the 
epithelium. LCs do not express DC-SIGN but can be identified by expression of Langerin 
(CD207), a lectin important in antigen recognition ofHIV.44 
DCs express CD4 and CCR545 but can also bind HIV virions independently of 
CD4, via interactions between gp120 and DC-SIGN, heparin sulfate proteoglycans 
(HSPG) or mannose C-type lectin receptor.44'46 Free virions have been observed to 
concentrate on the cell surface before internalization into a tetraspanin-rich compartment 
that may or may not be contiguous with the external membrane.47 Infectious virions can 
be held in this compartment until the DC contacts aT cell, and forms what is referred to 
as a virological or infectious synapse by which the virus is transferred to the uninfected 
CD4+ T cell.47'48 This is known as trans-infection, whereas an infection spread by a 
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productively infected DC is called cis-transmission (Figure 5).49 By either route, cell-cell 
transmission ofHIV is extremely efficient.49 
LC-expressed Langerin also binds gp120 but instead of facilitating infection, this 
interaction has been shown to cause the virion to be internalized into LC-specific 
phagocytic compartments called Birbeck granules and degraded, preventing transfer to 
peripheral blood derived T cells.50 This is thought to provide a natural barrier to HIV 
infection. However, another group showed that LCs preferentially transfer infectious HIV 
to memory T cells within in a tissue explant model, and that local viral expansion 
occurred in clusters of LC and memory T cells. 51 As the majority of the intraepithelial T 
cells in the vagina are CD45RO+ memory T cells,40 this may be an effective mechanism 
by which epithelial Langerhans cells transfer virus to T cells and enable local viral 
expansion. 
Whether vaginal DCs and LCs routinely become productively infected with HIV 
during viral sexual transmission is controversial, but productive infection has been 
observed in vitro when exposed to very high concentrations of virus, and in vivo in 
chronically infected HIV patients.49'52'53 Integration of viral DNA and subsequent virion 
production may not be as efficient in DCs/LCs, but if it occurs in the mucosa after HIV 
exposure it could also constitute a viable pathway by which infection is spread to local T 
cells and macrophages. 
CD4+ T cells are Jess prevalent in the ectocervicaJ and vaginal epithelium m 
comparison to CDla+ LCs, and generally reside near the basement membrane,40 but 
could conceivably encounter HIV infectious material without the assistance of an antigen 
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presenting cell. Few macrophages are found in the ectocervical and vaginal epithelium 
but are more prominent in the lamina propria and endocervix. 40 Oschenbauer et al. has 
reported that of the R5 tropic founder viruses they studied, all replicated more efficiently 
in T cells than macrophages, inferring that macrophages may not be the initial targets in 
HIV transmission.54 Macrophages did become productiVely infected but produced lower 
levels of virus than other R5 "prototypic highly macrophage tropic strains." This 
highlights the need for more studies to better understand the molecular mechanisms 
underlying the initial HIV transmission event. 
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Figure 5: Cis and Trans HIV Transmission. Transmission by a productively infected 
leukocyte to a non-infected leukocyte is called 'cis-infection' whereas transmission by an 
uninfected APC to aT cell is called ' trans-infection' . Top: An infected CD4+ T cell can 
transfer newly synthesized virus to a target cell via a virologic (infectious) synapse as is 
depicted above. This structure protects the virus from the outside environment as well as 
directionally sheds concentrated virus toward a new target cell, greatly increasing 
transmission efficiency. Middle: Similarly, this can happen between a productively 
infected APC and an uninfected target cell. Bottom: An antigen presenting cell, such as a 
DC or LC can pick up free virus from the extracellular environment, store it in an 
endocytic vesicle and transfer infectious virus while presenting viral antigens to the 
uninfected T cell via MHC class II. In this case, HIV proviral DNA is not integrated into 
the presenting cell, and as such is not productively infected. 
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Section 2.2: Cell-Free HIV Transmission 
The concentration of free virions in the semen (as measured by HIV RNA levels) 
is variable and dependent on several factors including duration of infection, recent or 
concurrent STI and antiretroviral therapy.55'56 In untreated men, levels of cell-free HIV 
have been reported to range between 0-1,000,000+ RNA copies per mL.55,57 
Antiretroviral treatment greatly reduces the amount of infectious material in semen and 
this is the basis of pre-exposure prophylaxis (PrEP) therapy, discussed in Section 7.58 
However as shown by our group and others, many men have breakthrough HIV shedding 
or persistently have high of seminal HIV RNA despite therapy. 59'60 In one of our recent 
publications, one quarter of men on stable anti-retroviral therapy had HIV in their semen 
with copy numbers ranging from 80 to 2560.60 Inflammation was identified as a major 
predictor of increased HIV shedding in the seminal compartment. 
HIV transmission by cell-free virus is easier to model than cell-associated HIV 
transmission and as such is the method used most widely in laboratory studies. In order to 
establish infection, cell-free HIV must survive the many innate immune defenses present 
in the female reproductive tract including low pH, trapping by mucus and anti-microbial 
molecules. There are several ways in which a virion could initiate infection through the 
cervicovaginal mucosa, as outlined in Figure 6. Mucus trapping of virions on the 
epithelial surface may prevent infectious material from breaching the mucosal barrier and 
enhance virus inactivation through prolonging exposure to innate anti-microbial 
compounds.61--63 However, this mechanism may also hold virions in close contact to the 
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epithelial surface, increasing the likelihood of contact with an HIV target cell. In 
addition, the stratum corneum of the vaginal and ectocervical epithelium in both humans 
and primates is a loose, spongy layer that may retain virions for several hours.64 
In a simian model of HIV transmission, cell-free SIV penetrated the vaginal 
mucosa with an hour; 18 hours post inoculation, the SIV+ cells in the vaginal epithelium 
were all determined to be of dendritic cell origin, whereas the subepithelial SIV+ cells 
were predominantly T cells and a few scattered macrophages.43 Of note, there were fewer 
DCs in the epithelium at 24hours than there were at 18, suggesting that these cells had 
become activated and infiltrated to peripheral lymph nodes. It is thought that DCILC 
capture of free virions at the epithelial surface is a likely mechanism by which cell-free 
HIV transmission occurs through non-inflamed epithelia and in the absence of 
microabrasions. Indeed, many studies have shown that humanized mice and primates are 
susceptible to HIV infection by intravaginal inoculation ofhigh titer cell-free virus. 15•65 
Some more controversial mechanisms of cell-free HIV transmission involve 
epithelial cells storing virions or virions being transcytosed through epithelial cells, a 
mechanism which could potentially facilitate direct contact with the resident immune 
cells that reside undemeath.4 1 Although transcytosis has been observed in vitro, it has not 
been demonstrated in vivo. There have also been a few reports that HIV c~n productively 
infect CD4 and co-receptor negative epithelial cells, although it should be noted that this 
is highly disputed.66•67 
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Section 2.3: Cell-Associated HIV Transmission 
The specific contribution ofCA-HIV transmission to the pool of new infections is 
unknown, but HIV residing in seminal leukocytes may persist longer than free virus as it 
is better protected against the innate immune system.9 There are several ways in which an 
infected immune cell could facilitate cell-associated viral transmission, as outlined m 
Figure 6. 
HIV -infected leukocytes can be numerous in the semen of infected men. The 
average ejaculate contains approximately 1x105 total seminal leukocytes, and in untreated 
HIV-positive men, 0.002-16% of the total leukocyte population harbors virus (as 
measured by proviral DNA).9 However, between 5 and 10% of the uninfected male 
population and up to 24% of the HIV -infected population have a condition known as 
leukocytospermia, which is characterized by more than 1x106 leukocytes per ejaculate.9 
As the number of total seminal leukocytes increase, so does the number of potential 
vectors of CA-HIV transmission. Additionally, increased proviral DNA in semen has 
been associated with recent inflammation.60 
It has long been recognized that during acute HIV infection, massive viral 
replication in gastrointestinal mucosa results in a rapid depletion of CD4+ T cells in that 
region, a condition which is partially restored upon initiation of anti-retroviral therapy.68 
Direct viral infection of gastrointestinal T cells, in addition to activation-induced cell 
death and CD8+ cytotoxic killing, leads to a 50% loss of intestinal CD4+ T cells within 3 
weeks of initial HIV infection.69•70 A recent publication from our laboratory highlights 
26 
that HIV infection severely depletes CD4+ T cells in the male genital mucosa as well, 
and similarly that seminal CD4+ T cell counts rebound following initiation of HAART. 71 
In this study, macrophages in semen far outnumbered CD4 T cells, and their numbers 
remained relatively constant throughout the course of infection. The relative abundance 
of macrophages in semen suggests that they may play an important role in HIV 
transmission.71 Based on this data, the experiments detailed in the Results section have 
focused on the potential role ofmacrophages in CA-HIV transmission. 
Leukocytes are capable of infiltrating into the vaginal epithelium and propagating 
infection in animal models and human explant tissue.72- 74 Le Grand et al. demonstrated 
that in macaques, vaginal exposure to SIV -infected leukocytes resulted in efficient and 
persistent infection. Just 24 to 48 hours after inoculation, SIV -positive donor cells were 
detected in proximal and distal lymphoid tissues while controls exposed to free virus did 
not become infected. In another study, fluorescently tagged HIV -infected lymphocytes 
added into the vaginal lumen of mice could be detected within the epithelium and 
draining lymph node at 24 hours after inoculation. Studies have also shown the efficacy 
of cell-associated HIV transmission across human epithelial mono layers and that this can 
be prevented by blocking leukocyte adhesion molecules. 75 Taken together, there is 
considerable data that suggests seminal leukocyte infiltration plays an important role in 
HIV transmission. 
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Figure 6: Potential Mechanisms of HIV Transmission. This illustration depicts various 
mechanisms in which an HIV-infected leukocyte could transmit infection to a new 
host. 1) An epithelial Langerhans cell (LC) inserts a pseudopod between adjacent 
epithelial cells into the vaginal lumen where it contacts free HIV virions. 2) An 
adherent, infected leukocyte is directly able to infect an LC by contacting dendrites 
extended toward the lumen for antigen sampling. 3) The infected seminal leukocyte 
migrates into the epithelium or lamina propria, where it encounters a greater 
concentration of target cells. 4) An abrasion or wound in the epithelium allows the 
diffusion of both free virus and infected leukocytes past the epithelial barrier and in 
close proximity to target cells. 5) Free virus from semen penetrates into the stratum 
corneum (porous layer), where it may be held until encountered by a target cell. 
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Section 3: Immune Defenses of the Lower Female Reproductive Tract 
Although often overlooked as an important part of innate immune defense, the 
vaginal and ectocervical mucosa constitute a major structural barrier to HIV transmission. 
The stratified squamous epithelium of the lower female reproductive tract is 20-30 cell 
layers thick76 and can be visually divided into four distinct zones: stratum corneum, 
intermediate, subrabasal and basal (Figure 5). The basal layer lies adjacent to the 
basement membrane and is composed of actively dividing epithelial cells. As the cells 
multiply, they are pushed up into suprabasal and then intermediate layers. The epithelial 
cells in the suprabasal, intermediate and basal layers have robust cell-cell junctions as 
viewed by immunofluorescence and electron microscopy.77 The female genital 
epithelium is further fortified by mucus, resident microbiota, innate antimicrobial 
molecules and innate immune cells that recognize pathogens through pattern recognition 
receptors (PRRs). 
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Histology: Credit Dr. Jeffrey Pudney 
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Figure 7: Anatomy ofthe Cervicovaginal Mucosa. The basal epithelial layer lies 
adjacent to the basement membrane that overlies the lamina propria, and is 
composed of actively dividing epithelial cells. As new cells are made, they push 
up into the suprabasal and then intermediate epithelial layers, taking on a more 
squamous (flattened) appearance. As the cells are pushed further upward into the 
stratum corneum (SC), they lose their nuclei, become filled with glycogen, and 
lose cell-cell attachments in preparation for sloughing into to the cervicovaginal 
lumen. 
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Section 3.1: Mucus 
Mucus has a very important role in trapping pathogens. Cervicovaginal mucus is 
composed of two types of mucins: membrane-associated and secreted. Secreted mucins 
are primarily synthesized in the numerous mucus-secreting glands and epithelial goblet 
cells of the endocervix, and flow into the lower female reproductive tract to lubricate the 
ectocervix and vagina.78 Secreted mucus is largely composed of mucins MUC5AC, 
MUC5B and MUC6. Membrane-associated mucins MUCl and MUC4 are expressed on 
the apical surface of the stratified squamous cells of the vagina and ectocervix. These 
mucins can extend up to 500nrn from the cell surface and complex to form a dense 
glycocalyx along the lumenal mucosa.78 The mucins produced in the female reproductive 
tract are organized in a dense fiber-like structure during non-ovulatory phases of the 
reproductive cycle but change to a more permeable globular arrangement around the time 
of ovulation to allow the passage of sperm.79 
Although it has been shown that the pore size in cervical mucus is large enough to 
permit the passage of viruses, cervical mucus still efficiently traps HSV (130nrn) in ex 
vivo experiments indicating that the viral envelope makes low affinity bonds with mucus 
strands.61 '80 
31 
Section 3.2 Microbiota and pH 
The vaginal microbiome plays an important role in mucosal immunity and 
resistance to STis. Immunoprotective Lactobacillus species (L. iners, L. crispatus, L. 
gasseri and L. jensenii) metabolize glycogen produced by mucosal epithelial cells to 
make lactic acid and maintain the vaginal pH at a healthy 4.5 or less81• Seminal plasma, 
which is slightly alkaline, buffers the vaginal secretions to a pH approaching neutral after 
intercourse, allowing for the survival and transmission of pathogens. 82 Lactobacilli can 
also produce bactericidins, sialidases, prolindases, proteases and hydrogen peroxide that 
help fortify vaginal innate immunity. 83'84 Bacterial vaginosis (BV) is a condition defined 
by a loss of Lactobacillus species resulting in increased vaginal pH, anerobic overgrowth 
and increased susceptibility to sexually transmitted pathogens such as T. vagina/is, C. 
trachomatis, N gonorrhoeae and HIV83 • 
Since BV is asymptomatic in 50% ofwomen and is present in a large percentage 
of the population, it is difficult to identify and treat women to reduce their risk of 
acquiring an STI. Recent reports estimate that 29% of US women85, 9-18% of UK 
women
12
•
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and >50% of rural , Ugandan women87 have BV. The current treatment for BV 
is antibiotic therapy but due to low effectiveness and high recurrence of disease, it is 
difficult to cure.83 BV remains an important cause of vaginal inflammation and cofactor 
for HIV transmission, especially in the developing world where prevalence is high. 11•12 
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Section 3.3: Pattern Recognition Receptors and Immune Activation 
Immunosurveillance in the vaginal and ectocervical mucosa is a delicate balance; 
on one hand, the innate immune system needs to be sensitive enough to detect potential 
pathogen invasion but on the other hand, a constant immune response against resident 
microflora and sperm would be harmful. One of the most formidable and sensitive 
methods of pathogen innate detection is accomplished through PRR engagement, 
particularly by toll-like receptors (TLRs) and C-type lectin receptors. 
TLRs are expressed by both epithelial and resident leukocytes, whereas C-type 
lectin receptors (i.e. Langerin and DC-SIGN) receptors are specific to phagocytic cells 
such as macrophages and dendritic cells. Engagement of these receptors by foreign 
pathogen associated microbial peptides (P AMPS) triggers a vast and complex immune 
response, resulting in cytokine and chemokine secretion, recruitment of effector cells, and 
cell activation and differentiation. 16'88 Included in this response is the release of pro-
inflammatory cytokines such as IL-l~, TNF alpha and IL-6, all of which activate NF-KB 
signaling pathways and upregulate HIV transcription. Engagement of toll-like receptors 
that detect viral nucleic acids (TLRs 3, 7, 8, and 9) result in the production of type I 
interferons, which act as potent inhibitors of HIV replication. 89'90 HIV genetic material 
can be recognized by TLRs 3, 7, and 8. Subsequent immune activation also results in the 
release of antimicrobial compounds that interfere with the pathogen life cycle such as 
SLPI, lysozyme, lactoferrin and defensins. 
Engagement of TLRs or C type lectins activates both innate and adaptive 
components of the immune response. TLRs recognize a variety of STI antigens as is 
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described in Table 4. In vitro, engagement of TLR's has been shown to both protect 
against HIV infection and facilitate it. As an example, intravaginal treatment with TLR3 
agonist poly I:C prevents HIV -1 transmission in mice9 1 but conversely, another study 
found that poly I :C induces LC maturation and subsequent HIV -1 transmission. 92 In the 
latter study, de Jong et al. also showed that infection of vaginal explants with Candida 
albicans and Neisseria gonorrhea not only triggered TLR signaling but also induced the 
production of TNF alpha, which enhanced LC trans-infection of T cells. Again, the 
concept of the 'delicate balance' in the genital mucosa is an important one; the induction 
of a protective antiviral immune response is at odds with the recruitment and activation of 
HIV target cells that facilitate HIV infection and replication. 
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PRR Expression Ligands (STI) 
macrophage, DC, peptidoglycan (GC,CT), porin B (GC), 
TLR2 epithelial phospholipmannan (CA), (HSV-2) 
macrophage, DC, 
TLR3 epithelial dsDNA (HSV -2, HPV, fllV) 
LPS (GC, CT), LOS (GC), mannan (CA), heat 
TLR4 macrophage, DC shock proteins (CT) 
macrophage, DC, 
TLR7 epithelial ssRNA (HIV) 
macrophage, DC, 
TLR8 epithelial ssRNA (HIV) 
TLR9 DC, epithelial CpG motifs (HSV) 
DC-SIGN macrop]1age, DC gp120 (HIV) 
Langer in macrophage, DC gp120 (HIV) 
Table 4: Pattern Recognition Receptors CPRRs) in the Lower Female Genital Tract 
Relevant PRRs and the STI antigens recognized from Neisseria gonorrhoeae (GC), 
Chlamydia trachomatis (CT), Candida albicans (CA), herpes simplex virus 2 (HSV -2), 
and human immunodeficiency virus (HIV). 
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Section 4: Mucosal Barrier Function: The Role ofTNF alpha 
It has been hypothesized that an important function of pro inflammatory cytokines 
such as TNFa is to increase the permeability of the epithelium to infiltrating leukocytes, 
putatively through NF-KB-induced cytoskeletal rearrangements or by upregulating 
epithelial production of matrix metalloproteinases (MMPs). TNFa has been shown to 
induce various degrees of barrier dysfunction in the intestinal, lung and nasal mucosa, 
although its function in the lower female genital tract is unknown.93--96 TNFa is detectable 
in the cervicovaginallavage fluid (CVL) ofwomen with genital inflarnmation97 and also 
in the supernatants of cultured vaginal epithelial cells exposed to pro-inflammatory 
stimuli.98•99 Nazli et al demonstrated that female genital columnar epithelial monolayers 
secreted TNFa when exposed to HIV envelope glycoproteins and became more 
permeable. In this study, the addition of a neutralizing antibody against TNFa restored 
barrier function. 100 
Inflammatory bowel disease is a well studied example of mucosal barrier 
dysfunction mediated by TNFa. Ye and coworkers have shown that TNFa treatment of 
Caco-2 intestinal cells causes degradation of IKB and release of NF-KB (p50/p65 
dimer). 101 Free p50/p65 then translocates to the nucleus to bind the myosin light chain 
kinase (MLCK) promoter region and increase transcriptional activity. The increased 
availability of MLCK causes more myosin light chain (MLC) to be phophorylated, 
ultimately resulting in contraction of the perijunctional actomyosin ring (Figure 8). 101 
This provides the mechanical force to overcome the interactions between junctional 
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molecules on adjacent cells and to separate them.33 While this mechanism has been 
described in simple epithelia, it is unclear if it plays a role in stratified mucosa. 
Of note, certain chemical agents have also been reported to enhance HIV 
infection through inflammation-enhanced epithelial barrier permeability. Former HIV 
candidate microbicides cellulose sulfate (CS) and nonoxynol-9 (N-9) efficiently 
inactivate the HIV virus in vitro and in animal models but were reported to increase HIV 
transmission in clinical trials through the induction of inflammation and barrier 
disruption. 102- 104 At the time, epithelial disruption was not routinely screened for and the 
need for improved systems for testing the safety of microbicides has received much 
attention since then.9 
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Figure 8: TNF alpha Enhances Transepithelial Leukocyte Migration via Several 
Potential Mechanisms. Left: Upon binding the TNF alpha receptor, (TNFR) TNF 
alpha induces a signaling cascade that results in the release of NF-KB from its 
inhibitor (IkB). NF-KB translocates into the nucleus where it acts to increase the 
transcription of pro-inflammatory mediators such as cytokines, chemokines and 
matrix metalloprotineases (MMPs) as well as myosin light chain kinase (MLCK). 
Right: 1.) MMP's and other proteinases act to cleave extracellular matrix components 
and epithelial junctional molecules as well as cleave and activate chemokines to 
facilitate leukocyte chemotaxis. 2.) TNF alpha signaling results in increased epithelial 
expression of leukocyte adhesion molecules such as ICAM-1. 3.) TNF alpha has been 
shown to cause dissociation of junctional molecules, including Z0-1, from the 
epithelial junction, which results in increased barrier permeability. 4.) TNF stimulates 
transcription of MLCK, which phosphorylates MLC and causes contraction of the 
peri-actina] cytoskeleton in simple columnar epithelium. 5.) The increased 
transcription of chemokines such as RANTES and IL-8 attracts leukocytes to the site 
of inflammation. 
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Section 5: Modeling the Site of Transmission 
A variety of models have been used to better understand the events surrounding 
HIV transmission, including human epithelial monolayers, human explant tissue, three 
dimensional (3D) human tissue reconstructions and animal models. These have yielded 
great insight into the mechanisms of HIV transmission under non-inflammatory 
conditions, but much more work needs to be done to elucidate the impact of 
inflammation and STis on both cell-free and cell-associated HIV transmission. 
Section 5.1: Epithelial Monolayers 
The stratified squamous mucosa of the lower female reproductive tract can be 
visually divided into 4 zones (Figure 5). The epithelial cells in each of these zones vary in 
protein expression, epithelial junctional arrangement, immune responsiveness and 
morphology. In vitro vaginal and ectocervical epithelial monolayers are most 
representative of the actively dividing cells found in the basal layer of the stratified 
mucosa. Both cell line-derived and primary epithelial monolayers are sensitive to 
inflammatory stimuli and the use of monolayers has been particularly informative in 
elucidating epithelial-pathogen interactions with infectious agents such as T. vagina/is, C. 
. 98 99 103 ws-101 A kn f h" d 1 · albzcans and N gonorrhoeae. ' ' ' wea · ess o t IS mo e IS that the basal 
epithelial cells are not normally directly exposed to pathogens, and the induced immune 
response may therefore be more exaggerated than would be expected in vivo. 103 Although 
some groups have used cervicovaginal monolayers to determine barrier resistance to both 
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cell-free and cell-associated HIV, this modeling system fails to account for the 
immunologic and barrier functions of the 20-30 layers of differentiated epithelial cells 
that would normally exist above the basal epithelial layer. 
Section 5.2: Human Explant Tissue 
The use of human ectocervical and vaginal tissue explant cultures allows for 
studies on stratified epithelia and has been very useful in determining some of the initial 
events in HN transmission. Ex vivo explant tissues support viral replication as they 
contain HIV target cells, and so it is possible to infect resident leukocytes in these tissues 
by immersion or adding virus to the apical surface. 108 The presence of allogenic, resident 
leukocytes allows for interaction between epithelial cells and leukocytes, resulting in a 
more in vivo-like immune response when the tissues are exposed to HIV and other STis. 
Cervicovaginal explant tissues have been successfully used to study genital N 
gonorrhea, herpes simplex virus 2 (HSV -2) and C. albicans infections both alone and in 
the context of enhanced HN transmission.92,109 
There are several caveats associated with the use of explant tissue. Often, little is 
known about the patients from which these tissues originate. 110 Treatment with hormones 
prior to surgery, the use of antimicrobial agents betadine and amphotericin B, and 
extensive tissue manipulation are common. Explant tissues deteriorate rapidly after their 
removal due to lack ofblood supply. The availability of fresh surgical tissue can also be a 
challenge and it is often not possible to perform donor matched replicate and control 
experiments; therefore these experiments are difficult to standardize.110 Although 
41 
techniques to seal the edges of the epithelium with agarose and 0 rings have been used, it 
has been debated as to whether the edges of the tissue are truly sealed. 111 Transmission 
through unsealed or partially sealed edges would mimic HIV infection through damaged 
but not intact epithelia. 
Section 5.3: Three dimensional epithelial reconstructions 
Several groups have created and published 3D reconstructed vaginal epithelial 
models. In 2010, Hjelm et al. reported the development of a stratified, spherical vaginal 
epithelial ball grown in a rotating bioreactor. The authors created this model specifically 
as a platform for high-throughput toxicity testing of new candidate microbicides as a 
compliment to existing animal and in vitro models. 112 Boucschbacher et al. have also 
published a semi-stratified vaginal epithelial reconstruction, similarly created from 
primary human vaginal epithelial cells.41 Like Hjelm et al. 's model, it displays some of 
the structural characteristics of normal human vaginal mucosa but has the additional 
advantage of being grown on culture inserts so that it receives nutrients from below. 
The data presented in this dissertation have made extensive use of another 3D 
epithelial reconstruction, the Epivaginal tissue culture system created by MatTek Corp™. 
EpiV aginal tissue cultures are composed of primary human vaginal epithelial cells seeded 
onto an autologous fibroblast layer (lamina propria) in a tissue culture insert. These 
cultures are fully stratified with a distinguishable stratum corneum, intermediate, 
parabasal and basal epithelial layers (Figure 10).113' 114 In addition, the edges of the 
EpiVaginal cultures are sealed to the plastic of the tissue culture insert, preventing 
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leakage problems that are common with explant tissue models and other tissue 
reconstructions. 11 o, 1 1 1 A drawback of this system is the lack of the complex resident 
leukocyte network that exists in vivo and to some extent in explant cultures, llO although it 
is possible to seed the EpiVaginal tissues with Langerhans cells (VLC-FT). 115 Secreted 
mucins present in the vaginal lumen are derived from the endocervix, and as such are not 
present in the EpiVaginal model. However, this model does permit the study of the 
differentiated vaginal epithelium and lamina propria in isolation from the immune system 
which is not possible in animal or explant models. Our laboratory participated in the 
d 1 d h · · f hi d lll3 114 s· E ·v · 1 · · eve opment an c aractenzat10n o t s mo e . ' mce p1 agma tissue 1s 
commercially available, reproducible, and viable for up to a week in culture, it was ideal 
for our studies. 113'114'116 
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A. 
B. 
Credit: Dr. JeffPudney 
Figure 9: EpiVaginal Tissue Model Resembles Human Vaginal Epithelium. A) H&E 
full thickness EpiVaginal tissue and B.) normal vaginal tissue. As seen here, the fully 
stratified EpiVaginal cultures are structurally similar to normal human tissue. 
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Section 5.4: Animal Models 
Section 5.4.1: Primate Models 
HIV-1 most likely originated when a simian immunodeficiency virus that infects 
chimpanzees (SIV cpz) crossed the species barrier to infect a human host. 117 SIV cpz and 
HIV infection of chimpanzees is the closest model of human HIV. Chimpanzees are no 
longer used as animal models due to their endangered status, and as such SIV insolates 
that infect smaller primates such as the rhesus macaque and pig-tailed macaque are now 
favored. 11 8•11 9 However, there are a few weaknesses to this model; first and foremost, 
primates are very expense to house and maintain. Also, animals are almost always pre-
treated with progesterone to thin the vaginal epithelium to reduce barrier function and 
then exposed to supra-physiologic concentrations of virus in order to attain appreciable 
rates of transmission. 11 9 As SIV and HIV cause different pathologies in their respective 
hosts, SHIV chimera viruses have been created to better represent HIV infection. 
Although there are many different SHIV strains available, these viruses are generally 
created by adding one or more HIV genes to an SIV backbone. 120•121 SHIV with HIV 
envelope glycoproteins has been particularly useful in vaccine trials. 120-124 
5.4.2: Humanized Mouse Models 
There are several ways to generate humanized mice, but the most relevant model 
for studying HIV transmission is created by transplanting CD38+ human progenitor cells 
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into immunocompromised mice, essentially reconstituting their immune system with 
human leukocytes. 125' 126 The BLT humanized mouse model is generated by taking this 
one step further; before transplanting CD38+ human cells, a piece of human liver is 
placed between two small pieces of thymic tissue and implanted under the kidney 
capsule, later growing into an organ that resembles a human thymus allowing T cells to 
be educated in a human instead of a mouse thymus. 126126 Macrophage/monocytes, T cells 
and dendritic cells effectively repopulate the genital mucosa of the BLT mice and less 
consistently in CD38+ transplant model.65' 127- 129 Denton et al. used the BLT mouse 
model to test emtricitabine (FTC)/ tenofovir disoproxil fumarate (TDF) as a microbicide, 
showing efficient cell-free vaginal HIV transmission in 7 out 8 in the control group and 
no transmission in the microbicide treated mice. 127 Khanna et al reported similar results 
for beta-cyclodextrin mediated blocking of cell-associated HIV transmission in 
humanized mice. 130 
The humanized mouse model is slightly less expensive and more available than 
the macaque model. Like the SIV macaque model, mice used in HIV transmission studies 
are often exposed to high concentrations of virus and are treated with progesterone to thin 
the vaginal epithelial barrier. 126 While the leukocytes in the reproductive tract are human, 
the epithelium and innate immune defenses are still murine. Even with these caveats, 
both the macaque and mouse models have yielded insights into the mechanisms of HIV 
transmission. 
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Section 6: The Role of Inflammation in Cell-associated HIV Transmission 
As mentioned previously, inflammatory mediators enhance HIV replication and 
promote chemotaxis of leukocytes from the blood to the site of infection where they play 
a role in immune defense, but also may serve as targets for HIV infection. It is our 
hypothesis that these two processes work in concert to facilitate cell-associated HIV 
transmission in women with genital inflammation. In order to infiltrate inward from the 
vaginal lumen, an infected seminal leukocyte would likely have to adhere to and move 
between epithelial cells potentially in response to a chemokine gradient. In this scenario, 
the interepithelial tight junctions would have to open to allow passage. Paracellular 
migration (moving through epithelial cells, as opposed to between them) has been 
described for leukocyte migration through endothelial cells 131 but has not been 
documented through epithelial cells. We hypothesize that TNF alpha and other 
proinflammatory cytokines in the epithelium upregulate the expression of matrix 
metalloprotinases, chemokines and leukocyte adhesion molecules that may attract and 
assist in leukocytes migrating into the vaginal and ectocervical epithelium. In addition, 
inflammation-induced epithelial junctional rearrangement could play a role in enhanced 
transcellular leukocyte migration. 
6.1 Matrix Metalloproteinases (MMPs) 
Matrix metalloproteinases (MMPs) are a class of proteinases made by many cell 
types, including epithelial cells and leukocytes. They are produced as zymogens and once 
47 
cleaved, become active enzymes. (Appendix A) MMPs are best known for their ability to 
cleave components of the extracellular matrix, such as collagen and laminin, although 
they also target cell surface receptors, growth factors, cytokines and epithelial junctional 
molecules. 132 Often the cleavage by-products of these reactions act as signaling 
molecules and propagate the inflammatory response. MMPs are responsible for enabling 
leukocyte migration through the enzymatic processing of chemokines and chemokine 
receptors resulting in the creation of a chemotactic gradient. 133 It has been shown in 
knockout mouse models that deficiencies in MMP 2, 3, 7, 8 and 12 all result in defective 
leukocyte influx and/or egress in inflammatory models. 133 Uncontrolled MMP9 activity 
has been causally linked to epithelial barrier disruption and symptoms of inflammatory 
diseases such as dry eye. 134 MMP's have also been demonstrated to cleave epithelial 
junctional molecules Z0-1, occludin and E-cadherin and have an important role in 
facilitating leukocyte migration.m,m ,l35-l 37 
6.2 Chemokine Gradients 
Chemokines are secreted by many cell types in response to inflammation or 
injury. These small immunologic mediators are involved in many facets of the immune 
system including leukocyte development, immune surveillance, immune priming, 
effector responses and immune regulation. 138 Chemokines bind G-coupled protein 
receptors on the leukocyte cell surface to induce chemotaxis, the directed migration of the 
leukocyte to foci of inflammation. There are two major families of chemokines, CXC and 
CC, named for their invariant cysteine residues88• Immune cell subsets express 
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characteristic chemokine receptors, meaning that each chemokine attracts specific 
leukocyte populations.88 For example, IL-8 (CXCL8) strongly recruits neutrophils but has 
no discernable effect on monocytic cells. 88' 139 Table 5 shows some relevant chemokines 
secreted by epithelial cells, their cognate receptors, and responsive leukocytes. As has 
been noted previou~ly, HIV requires a chemokine co-receptor (CXCR4 and CCR5) for 
C' 
entry into the host cell and the chemokines that normally bind these receptors (SDF-1, 
RANTES, MIP 1-alpha and -beta) act as competitive inhibitors for gp120 binding.29,140 
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Chemokine Receptor(s) Cells Attracted 
CXCLI (GROa) CXCR2 neutrophils, naive T cells 
CXCL8 (IL-8) CXCRl , CXCR2 neutrophils, naive T cells 
CXCL9 CXCR3 activated T cells 
CXCLlO CXCR3 activated T cells 
CXCLll CXCR3 activated T cells 
CXCL12 (SOFia/b) CXCR4 naive T cells 
monocytes, DCs, T cells, NK 
CCL3 (MIPla) CCRl , CCR3, CCR5 cells 
monocytes, DCs, T cells, NK 
CCL4 (MIPlb) CCRl , CCR3, CCR5 cells 
monocytes, DCs, T cells, NK 
CCL5 (RANTES) CCRl , CCR3, CCR5 celJs 
CCL20 (MIP3a) CCR6 DC, Tcells 
CX3CL1 (fractalkine) CX3CR1 monocytes, T cells 
Table 5: Inflammation-Induced Epithelial Chemokine Expression. Epithelial cells 
produce chemokines in response to inflammatory stimuli. Some relevant 
chemokines, the receptors they signal through and the immune cells attracted by 
those chemokines are listed above. Of note, chemokines SDF-1 alpha, MIPla, 
MIPlb, and RANTES engage HIV co-receptors and as such act as competitive 
inhibitors ofHIV entry. 
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Section 6.3: Leukocyte Adhesion Molecules 
One of the classic hallmarks of inflammation is the upregulation of leukocyte 
adhesion molecules on epithelial and endothelial cells to assist leukocyte migration to the 
site of injury or inflammation. There are three major classes of leukocyte adhesion 
molecules: selectins, integrins and intercellular adhesion molecules. Selectins, such as P-
and E-selectins are membrane glycoproteins that initiate leukocyte-endothelial 
interactions to assist leukocyte migration out of the bloodstream. 141 Integrins, such as 
leukocyte functional antigen-! (LF A-1) and macrophage- I antigen (Mac- I), are present 
on leukocytes and bind endothelial and epithelial-expressed intercellular adhesion 
molecules such as ICAM-1.88 ICAM-1 expression is upregulated in many types of 
epithelial inflammation, particularly in response to TNF alpha, and its expression 
facilitates leukocyte migration through the epithelium. 142' 143 A leukocyte responding to a 
site of inflammation could strategically use distributed leukocyte adhesion molecules as 
footholds to move through the lamina propria and into the epithelium. Epithelial 
junctional molecules JAM-A, JAM-C, and E-cadherin have also been shown to act as 
leukocyte adhesion receptors and participate in the migration of macrophages and/or T 
cells. 144--147 The role of these junctional molecules in normal epithelial junctions and 
during inflammation is described in greater depth in Section 6.4. Leukocytes have also 
been reported to form rapid, low-affmity interactions with the extracellular matrix (ECM) 
in an integrin-independent manner that may further assist in chemotaxis. 148 
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Section 6.4: Epithelial Junctional Molecules 
An important function of pro-inflammatory cytokines, particularly TNF alpha, is 
to increase the permeability of the epitheJium.92- 94'133' 149 This happens at the level of 
cytoskeletal rearrangement150 (Section 4) and rearrangement of epithelial junctional 
molecules.92•93•151 - 153 The expression of junctional adhesion molecules in the 
cervicovaginal epithelium has not been weJI described and the mechanisms that allow 
vaginal and cervical epithelial junctions to come apart for selective passage of leukocytes 
are still not well understood. There are several epithelial processes that could play a role 
in apical to basal leukocyte transmigration, including the selective internalization of 
epithelial junctional molecules/ 51 degradation of junctional molecules by proteases, 132•153 
and leukocyte binding of epithelial adhesion molecules.146•147•154 The studies presented 
here focused on tight junctional molecules claudin-1, zona occlusions 1 (Z0-1 ), 
junctional adhesion molecule A (JAM-A), and occludin as well as adherens junctional 
molecules E-cadherin and alpha catenin and desmosomal junctional adhesion molecule C 
(JAM-C) as these molecules have been shown to be expressed in other mucosal epithelia. 
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Leukocyte Roles in Inflammation-induced Barrier 
Adhesion Disruption 
Receptor 
Molecule Ligands 
Transmembrane component ofTJ. Altered in 
inflammatory bowel disease and changes in JAM-
A localization are correlated with increased 
JAM-A LFA-1 
epithelial permeability.95'146'151 
Transmembrane component ofTJ. Altered in lung 
and intestinal inflammation. Claudin-1 null mice 
Claudin-1 
unable to maintain epidermal barrier 
function. 155'156 
Non-essential transmembrane component ofTJ. 
TLR2 induced cleava~e in lung, linked to 
Occludin leukocyte migration.' 
3
'
157
'
158 
Essential component of intracellular TJ 
scaffolding network, decreased expression in 
ulcerative colitis, Crohns disease, rhinitis and 
Z0-1 asthma.93,94,I52 
Only transmembrane component of adherens 
junction. TLR2 induced cleavage in lung, linked to 
E-cadherin alpha E beta 7 leukocyte migration. 
147
'
153 
Intracellular scaffolding molecule. Promotes stable 
alpha cell-cell contacts. Decreased in asthma ;atients, 
catenin may regulate leukocyte migration.
159
,
16 
JAM-C Mac-1 none known 
Table 6: Epithelial Junctional Molecules: Functions in Barrier Maintenance and 
Leukocyte Migration. Junctional molecules of interest and their roles in 
inflammation, barrier disruption and leukocyte migration. 
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Section 7: Topical Microbicide Development 
In the absence of an effective HIV vaccine, there has been much interest in the 
development of topical compounds that could be applied at the site of infection to reduce 
or prevent HIV transmission. Such products, referred to as microbicides, could 
theoretically be delivered by various systems, including gels, vaginal rings, dissolving 
film, etc. Over the last two decades, many candidate microbicides have been evaluated in 
clinical trials. The first proposed microbicides were membrane-disrupting surfactants 
(such as nonoxynol-9 and cellulose sulfate); these compounds had potent anti-HIV 
activity in vitro and in animal models, but failed to provide protection in clinical trials 
d . . 11 nh d HIV . . 102 161 162 0 h h an m some mstances actua y e ance transmissiOn. ' ' t er approac es 
aimed to prevent attachment to target cells in the genital mucosa (polyanions such as 
PR02000) or chemically maintain low vaginal pH in the presence of semen (BufferGel), 
but these too failed to prevent HIV transmission to women. 163' 164 Recently, a prophylactic 
oral drug regimen and a gel-based microbicide containing the antiretroviral drug 
tenofovir have been shown to significantly reduce HIV transmission in clinical trials. 165 
Although three separate clinical trials reported the tenofovir pre-exposure prophylaxis 
(PrEP) resulted in a 44%-75% decrease in transmission in both heterosexual and 
homosexual individuals, it should be noted that other trials have failed to show 
efficacy. 166 The VOICE clinical trial (heterosexual women) found that gel-based and oral 
tenofovir and Truvada (combination tenofovir/ emtricitabine) was not efficacious in 
preventing HIV transmission women. 167'168 The FEM-PrEP clinical trial also failed to 
54 
demonstrate prevention of HIV transmission in women treated prophylatically with 
Truvada. 166 In addition, animal studies have found that tenofovir-containing microbicides 
are less efficacious against cell-associated HIV. 169 Clearly, more studies need to be 
performed in order to evaluate the use of anti-retroviral drugs to prevent HIV 
transmission, and in what situations it might be most effective. To date, few studies place 
a great emphasis on HIV transmission in individuals with genital inflammation or on the 
contribution of CA-HIV to overall transmission rates. Elucidating these mechanisms of 
transmission may i(lform the future development of microbicides, as well as to help 
understand the inconsistencies in the aforementioned clinical trials. 
Section 8: Objective and Specific Aims: 
There are not many studies on leukocyte migration through the epithelium and 
extracellular matrix, and even fewer on apical to basal transmigration of foreign 
leukocytes. As cervicovaginal inflammation enhances HIV transmission, it was our 
purpose to understand if seminal leukocyte immigration into the female genital 
epithelium is enhanced by inflammatory processes such as the upregulation of leukocyte 
adhesion molecules, pro-inflammatory cytokine/chemokine secretion and epithelial 
junctional rearrangement. This necessitated the development of an in vitro system that 
would allow the identification of inflammation-induced changes in the epithelium that 
affect the inward infiltration of seminal HIV -infected leukocytes. To our knowledge, the 
effect of genital inflammation on the infiltration of seminal leukocytes has not yet been 
studied. Since STis have a great impact on susceptibility to HIV, and cell-associated HIV 
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transmission has been shown to be very effective in vitro and in animal models, this 
constitutes a rather large black box in the fields of HIV transmission and prevention. As 
such, we set out to investigate if genital inflammation enhances in the inward infiltration 
ofHIV-infected leukocytes through the following specific aims: 
Specific Aim 1: Characterize the expression of adhesion molecules in the EpiVaginal 
tissue model 
1.1 We compared the expression of key epithelial junctional adhesion 
molecules claudin-1, JAM-A, JAM-C, E-cadherin, Z0-1 and occludin 
between human vaginal tissue and the EpiVa&inal tissue culture model. 
1.2 We compared the expression of the aforementioned junctional molecules 
in EpiVaginal tissue under normal and TNF alpha-induced inflammatory 
conditions. 
1.3 We assessed whether changes in junctional molecule expression and/or 
localization correlated with alterations in epithelial permeability. 
Specific Aim 2: Assess apical to basal infiltration of labeled leukocytes through 
EpiV aginal tissues by confocal microscopy 
2.1 We visualized the infiltration of apically-added primary and cell line 
derived leukocytes into EpiVaginal tissue cultures during normal and 
TNFa -induced inflammatory conditions. 
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2.2 We identified factors (chemokine secretion, expression of leukocyte 
adhesion molecules, changes in barrier permeability) that may enhance 
apical to basal leukocyte infiltration. 
Specific Aim 3: Determine the ability ofHIV infected macrophages to infiltrate into and 
below the epithelial layer. 
3.1. We used confocal microscopy to track MDMs infected with 
fluorescently-tagged HIV infiltrating from the EpiVaginal surface into the 
tissue. 
Specific Aim 4: Determine whether leukocyte infiltration can be blocked with antibodies 
directed against key adhesion molecules. 
4.1. We assessed ICAM-1 blocking antibodies as a potential mechanism to block 
apical to basal leukocyte infiltration. 
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Materials and Methods 
Human Ectocervical Tissue Culture 
This study was approved by the Institutional Review Boards of Boston University 
in Boston, MA. Ectocervical tissue specimens were obtained from discarded surgical 
samples from reproductive-aged (18-49 years) and otherwise healthy hysterectomy 
patients. Within 45 minutes of surgical removal from the patient, the tissues were either 
fixed and embedded in paraffin or grossly dissected to remove extraneous connective 
tissue leaving the epithelium and lamina propria intact, and then cut into pieces 
approximately 1 cm2 in size. Individual pieces of the explant tissue were placed apical 
side up in a 12 well tissue culture plate (Costar Coming Inc.) and cultured in lmL of 
MatTek VEC FT-100 maintenance medium (MatTek Corp.) 5x106 activated U937s or 
primary monocyte-derived macrophages (MDMs) were added to the apical surface of 
explant tissue and allowed to infiltrate. Leukocytes were added into a cut pipet tip that 
was gently pushed into the epithelial surface to prevent infiltration through the cut tissue 
edges, and the areas imaged by microscopy were near the middle of the explant. Tissues 
were then fixed for scanning electron or confocal microscopy. 
EpiVaginal Tissue and TNFa-induced Inflammation 
Full (FT-VEC 100) or partial thickness (PT-VEC 100) EpiVaginal tissues 
(MatTek Corp.) were placed on ice, packed and transported from the MatTek facility in 
Ashland, MA to Boston University Medical School. Upon arrival, the tissue was allowed 
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to equilibrate overnight at 37°C and 5% C02. The following day, tissues were placed in 
500J..LL of fresh medium (proprietary, MatTek Corp.) and were treated apically with 50J..LL 
of 0.1J..Lg/mL, 1J..Lg/mL, 10J..Lg/mL recombinant human TNFa (Invitrogen), 50J..LL of 
25J..Lg/mL Polyinosinic:polycytidylic acid (poly (I:C)) or medium alone for 24 hours. 
Immunofluorescence Microscopy for Localization of Tight Junctions 
Human and EpiV aginal tissue sections were embedded in paraffin, mounted on 
glass slides, de-waxed, and re-hydrated in a graded series of alcohols. Prior to staining, 
sections underwent antigen retrieval (pH 6 citrate buffer, Dako Carpinteria CA) in a 
decloaking chamber (Biocare Medical). Sections were blocked with 10% normal donkey 
or goat serum and were then treated with a primary antibody against one of the following 
epithelial adhesion molecules: JAM-A (hJAM-A affinity purified goat IgG, R&D 
Systems), JAM-C (hJAM-C purified mouse IgG, R&D Systems), E-cadherin (mouse 
IgG 1, Invitrogen), Z0-1 (Z0-1 rabbit polyclonal, SantaCruz Biotech, Inc.), occludin 
(rabbit polyclonal Ig Zymed Laboratories), claudin-1 (rabbit polyclonal Ig Zymed 
Laboratories) or ICAM-1 (rabbit polyclonal, Invitrogen). Tissues were then incubated 
with anti-mouse, anti-goat, or anti -rabbit lgG conjugated to Cy3 (Jackson Labs) to 
visualize primary antibody binding. All sections were mounted with V ectashield 
mounting medium containing DAPI as a nuclear counterstain and analyzed under an 
epifluorescence microscope. (Olympus model BH-2, Center Valley PA) 
59 
Viability and Permeability Assays 
Transepithelial electrical resistance (TEER) was performed at the conclusion of 
each experiment by submerging EVOM STX2 Chopstick electrodes (World Precision 
Instruments) into the tissue culture insert and the outside well. The probe was connected 
to a voltohmeter (World Precisions Instruments), which measures electrical resistance. 
Tissues with a resistance of less than 100 ohms or that appeared 'leaky' were not 
included in analysis. MTT assay was utilized to assess epithelial cell viability. The 
yellow tetrazole in the MTT reagent (Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) is reduced to purple formazan in cells with active mitochondria. Twenty-two 
hours after TNFa treatment, 300J.1L of MTT reagent was added to the basal medium for 2 
hours. At the conclusion of 1NF-treatment, the tissues were submerged in 70% 
isopropanol overnight to extract the purple dye. Absorbance was read at 570nm. To 
assess for apoptosis, terminal deoxynucleotidyl transferase UTP nick end labeling assay 
(TUNEL) (Roche) was performed on EpiVaginal tissue sections. Staining was analyzed 
at 20x on an epifluorescence microscope. (Olympus model BH-2, Center Valley PA) 
Cytokine Quantification 
Tissue culture supernatants were collected and cytokines were quantified using 
IL-6, IL-8, and RANTES Quantikine kits (R&D systems) as per manufacturer 
instructions and was read at 450nm. 
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Macrophage Cell Culture 
U937 monocytes (ATCC) were grown in RPMI 1640 medium supplemented with 
10% fetal bovine serum, 1% L-glutamine and 1% penicillin-streptomycin (all from 
Invitrogen) at 37°C and 5% C02. To activate/mature the U937 monocytes, lOnM phorbol 
12-myristate 13-acetate (PMA) was added to culture medium for 36 hours, after which 
the U937 cells became adherent. Primary macrophages were isolated by Ficoll gradient 
centrifugation and adherence onto plastic tissue culture flasks. Non-adherent cells were 
removed after 24 hours, and adherent macrophages were cultured for 7-1 0 days at 3 7°C 
and 5% C02 in RPMI with 10% human serum, 10% fetal bovine serum, 1% L-glutamine, 
1% HEPES and 1% penicillin-streptomycin (all from Invitrogen). Immediately before 
use, adherent PMA-activated U937 macrophages or MDMs were washed once with PBS 
and incubated with Versene (Invitrogen) or Cell Stripper (CeliGro, Manassas Virginia) at 
37°C for 30 minutes to 1 hour to loosen attachment to the tissue culture plate. Cells were 
removed by vigorous pipetting and washed twice with tissue culture medium. 
Scanning Electron Microscopy 
Fixed ectocervical samples dehydrated to 100% ethanol as previously described.77 
These samples were then placed in the specimen chamber of a critical point drier 
(Polaron Inst. PA). The dried samples were then mounted on SEM aluminum stubs with 
the mucosal surface facing up, coated with gold/palladium in a Hummer sputter coater 
(Technic VA), and viewed in an ETEC Autoscan microscope (Hayward CA) operated at 
20kv. 
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Leukocyte infiltration assays 
Macrophages were incubated with either CMFDA (lflg/mL) or CMPTX 
(2f.lg/mL) Live Cell Trackers (Molecular Probes) for 15minutes prior to infiltration 
experiments. Labeled cells, usually 1 x 106 were suspended in 50flL of MatTek medium, 
added to the apical surface of full thickness Epivaginal tissues and cultured at 37°C and 
5% C02 for up to 4 hours. As a control, 1x 106 inert 10flm and 100nm Cy3-labeled 
microbeads (Molecular Probes) suspended in 50flL MatTek medium were added to the 
apical surface of EpiVaginal tissue and incubated for 2 hours. Tissues were then fixed in 
10% formaldehyde and immersed apical-side down in Vectashield mounting medium 
(Vector Laboratories, CA) in a glass bottomed .culture dish (MatTek Corp., Ashland MA) 
for analysis by confocal microscopy. 
Blocking Experiments 
In some cases, 50f.1L of 50f.1g/mL ICAM-1 blocking antibody or sheep isotype 
control IgG (both R&D systems) was added to the apical tissue surface of full thickness 
EpiVaginal tissues for 1 hour before the addition of leukocytes. CMFDA or CMPTX 
labeled macrophages were then suspended in 50flL of MatTek medium, added to the 
apical surface ofthe Epivaginal tissues and cultured at 37°C and 5% C02 for 2 hours. 
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Confocal Imaging and Image Analysis 
Tissues were imaged using a Zeiss 710 confocal microscope and Zen2009 
software in the Boston University Imaging Core Facility. Each tissue was visually 
divided into 5 zones and 1 Z-stack (3Jlm sections) was taken at magnification of lOx 
from each of the five areas. A total of 5 Z-stacks were taken per tissue, representing about 
10% ofthe total imageable area of each tissue insert. The precise location of each imaged 
area was chosen at random from flat sections of tissue within each of the 5 areas; tissue 
edges were avoided because cells and beads tended to pool in indentations that occurred 
at the edges of the tissue. 
Z-stacks were imported into Image J and merged into 30Jlm sections using the 
Grouped ZProjector plug-in. Infiltrating macrophages and microbeads were counted at 
seven different depths: 0-30Jlm, 31-60Jlm, 61-90Jlm, 91-120Jlm, 121-150Jlm, 151-
180Jlm, and 181-2l0Jlm as the epithelium in MatTek tissue is approximately 200-250Jlm 
thick. Images were prepared for counting by first converting to a binary image, using the 
Watershed function to separate adjacent cells, and then applying Analyze Particles to 
count particles over 50 pixels in size. The average number ± SEM of cells or beads at 
each depth was calculated. 3D reconstructions were created using IrnageJ and Zen2009 
software. 
Western Blot 
EpiVaginal tissues were homogenized in a lysis buffer consisting of 1 OmM 
Imidazole, lOOmM NaCl, lmM MgC12, 5mM Na2 EDTA, 1% Triton X, 0.87 mg/mL 
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beta octyl glucoside, dH20 and fresh protease inhibitors (Invitrogen) were added 
immediately prior to use. 25/lg of protein lysate was separated by SDS PAGE under 
reducing conditions and transferred to a PDVF membrane. The membrane was blocked 
overnight in 4% milk+ TBST at 4°F. At this time, the membranes were incubated with a 
primary mouse monoclonal antibody against ICAM-1 (Santa Cruz, 1:1,000) for 2 hours 
and then a secondary horseradish peroxidase labeled donkey anti-rabbit antibody 
(I: 1 0,000) for 1 hour, both at room temperature. All membranes were visualized using 
ECL Plus Detection System (GE Healthcare) and exposure to Hyperfilm ECL (GE 
Healthcare). Analysis of the resulting bands was performed with ImageJ. 
Microarray 
Affmetrix Genechip Human Gene 1.0 ST arrays were performed on RNA from 
six EpiVaginal tissue treatment groups: full thickness (FT) VEC100 treated with 50/lL 
medium alone, FT-VEC100 treated with 50/lL of 10/lg /mL TNFa, FT-VEC treated with 
50/lL of25!lg/mL poly (I:C), a TLR 3 ligand, partial thickness (PT) VEC100 treated with 
50/lL medium alone, PT-VEC100 treated with 50/lL of 10/lg/mL TNFa and PT-VEC 
treated with 50/lL of 25 /lg/mL poly (I:C). All treatments were for 24 hours. For each 
treatment group, 3 EpiVaginal tissues were pooled and homogenized in Trizol. The 
samples were then sent to the Boston University Microarray Core for mRNA extraction 
and microarray analysis. Data analysis was also performed by the BU Microarray Core 
Facility. Differential expression of genes was considered significant if the log2 
transformation value was greater than 1, signifying a 2 fold change in mRNA expression. 
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Generation of HIV Construct 
The Lai Bal iGFP/psPAX2/VSVG HIV construct was graciously provided by 
Rahm Gummuluru (Boston University). To generate a CCR5 tropic fluorescent virus 
Lai!Bal-iGFP provirus clone, the Sali-BamHI fragment containing the entire env gene of 
Lai/Bal env was exchanged into Lai-iGFP provirus plasmid (Puryear et al. , 2013 Plos 
Pathogens). Infectious CCR5 tropic virus HIV-1 Lai!Bal-iGFP was derived from 
transient transfection of HEK293T cells. HEK293T cells were transfected with 3Jlg 
Lai!Bal-iGFP plasmid per well of a 6-well plate with 0.25M CaCh and equal volume of 
2xBBS. The next day, the cells were gently washed with PBS and the media replaced. 
Cell free supernatants were harvested day 3 post transfection, filtered of cell debris 
through 0.45Jlm syringe filter, and further purified and concentrated via 
ultracentrifugation through a 20% sucrose cushion in lOmM HEPES, 140mM NaCI at 
IOO,OOOg and 4°C for 90min with a SW32Ti rotor (Beckman). Virus pellet was 
resuspended in IOmM HEPES, 140mM NaCl, aliquoted and stored at -80C until used. 
Virus stock was measured for p24gag via p24 ELISA. 
HIV-irifection of MDMs 
7 day old, adherent MDMs in 1 Ocm tissue culture plates were incubated with 3 Jlg 
p24 Lai Bal iGFP/psPAX2/ VSVG overnight with Polybrene (lOJlg/mL, Sigma) and 
washed four times with PBS the following morning. The macrophages were cultured for 
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an additional 2 days before the infiltration assay was performed (see Leukocyte 
Infiltration Studies). Briefly, the MOMs were stained with CMPTX (red live cell stain) 
and added to the apical surface of TNF -treated EpiVaginal tissue for 2 hours, after which 
they were fixed in 10% formaldehyde and imaged on the Zeiss 710 confocal microscope. 
Double positive cells were counted using ImageJ and reported as median values. 
Statistical Analysis 
Statistical analysis ofELISA quantification, TEER, MIT, bead infiltration assays 
and macrophage infiltration cell counts was performed using the Mann Whitney U test. 
The infiltration of GFP+ HIV infected MOMs was performed using Wilconxin Signed 
Rank Test. 
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Chapter 1: Structure and Function oflntercellular Junctions in Human 
Cervicovaginal Mucosa 
Chapter 1 Introduction 
Epithelial surfaces in multicellular organisms constitute an interface that separates 
the individual from the environment. Epithelial intercellular junctions maintain the 
integrity and organization of epithelia by regulating molecular and cellular traffic and by 
providing a physical barrier to pathogen invasion. There are three major types of cell-cell 
structural adhesions between epithelial cells: tight junctions, adherens junctions, and 
desmosomes. 170•171 Tight junctions (zonula occludens) are composed of transmembrane 
proteins that make contact across the intercellular space and create a seal to restrict 
paracellular diffusion of molecules across the epithelial sheet. 170•172 Tight junctions also 
have an organizing role in epithelial polarization by limiting the mobility of membrane-
bound molecules between the apical and basolateral domains of the plasma membrane of 
each epithelial cell. 170•173 Adherens junctions (zonula adherens) connect bundles of actin 
filaments between cells to form a continuous adhesion belt usually just below the tight 
junctions. 170•172 Desmosomes (macula adherens) connect keratin intermediate filaments 
from cell to cell to form a structural framework of great tensile strength.174 
Epithelial intercellular junctions contain distinctive combinations of specialized 
molecules. Tight junctions are comprised of a network of inter-membrane fibrils of 
transmembrane proteins including occludin, claudins and junctional adhesion molecules 
(JAMs). 170•173 These proteins are linked to the cytoskeleton by cytosolic proteins such as 
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the zona occludens (ZO) proteins, which serve as adapter molecules and recruit 
regulatory proteins to the tight junction. The transcellular component of adherens 
junctions is comprised of epithelial cadherin (E-cadherin) dimers, anchored to the 
cytoskeleton via vinculin and alpha and beta catenin.172 Desmosomal adhesion proteins 
JAM-C, desmoglein and desmocollin are anchored to intermediate filaments via a 
scaffolding network ofplakin and armadillo proteins.154•174 
Although once thought to be a rigid, static structure, the composition of the tight 
junction can change rapidly in response to a range of stimuli including estrogen, growth 
factors, calcium concentration, inflammatory mediators and pathogen invasion.94•173•175 
Tight junctions are responsible for the sealing of the epithelial barrier as well as for the 
selective passage of small ions and fluid, which may be reliant on ion channels created by 
pore-forming claudins.176 As visualized by freeze-fracture electron microscopy, epithelial 
tight junctions contain 4 to 9 protein strands; the number of strands directly correlates 
with the epithelial resistance of the tissues. 173•177 
A specialized mucosal epithelium covers internal surfaces. Much of the current 
knowledge of mucosal epithelial junctions is based on the gastrointestinal and pulmonary 
tracfs.170•171 Since the lower female genital tract is the primary site of infection by a 
number of sexually transmitted bacteria and viruses, an in depth understanding of the 
structure and function of epithelial junctional complexes at this site is crucial to 
understanding STI invasion and immune defense. However, only a few studies have 
begun to characterize intercellular junctions in human cervicovaginal tissue or cell 
lines.41 •100•178•179 We therefore undertook this study to systematically characterize the 
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structure, location and molecular composition of epithelial intercellular junctions in 
normal human cervical and vaginal tissues. Our study focused on JAM-A, JAM-C, E-
cadherin, claudin-1, occludin and Z0-1, junctional proteins thought to be key regulators 
of epithelial permeability, junctional integrity and leukocyte infiltration.94•146•154•171 •173 We 
also performed studies with stratified squamous epithelial tissue to determine whether the 
apical layers of cornified cells, which lack tight junctions, are permeable to high 
molecular weight immunological mediators. 
Chapter 1 Results 
Visualization of cervical epithelial junctions by electron microscopy 
Scanning electron microscopy examination of the endocervical luminal surface 
revealed a coherent, tightly packed layer of epithelial cells with abundant microvilli (Fig. 
1 Oa). In contrast, the lumenal surface of ectocervical epithelia was composed of flattened, 
partially detached squamous epithelial cells (Fig. 1 Ob ). 
When examined by transmission electron microscopy, endocervical epithelial 
cells exhibited the classical tri-partite junctional complexes typically associated with 
secretory mucosa. In the apical region, opposing endocervical cells were joined by 
juxtaluminal tight junctions, where fusion of adjacent cell membranes effectively seal the 
apex of each cell to prevent intercellular passage of luminal contents (Fig. lla, b). Below 
the tight junctions, adherens junctions were observed to form an adhesive band around 
adjacent cells helping to maintain cohesion of the epithelium. Finally, desmosomes were 
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observed below the adherens junctions, spaced at intervals around the cell circumference. 
(Fig. lla, b) 
In the ectocervical stratified squamous epithelium, exclusionary epithelial 
junctions were found beginning 3-4 cellular layers from the lumenal surface, and 
abundant adherens junctions between neighboring cells were visualized in the supra-basal 
layers (Fig. llc, d). In contrast the apical epithelial cells of the ectocervix, which are 
cornified and filled with glycogen, did not show any specialized adhesion junctions. 
Instead they were loosely connected by short cellular projections that studded the surface 
of these cells (Fig. lle, f). 
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Figure 10: Human Endo- and Ectocervical Lumenal Surfaces Viewed by Scanning 
Electron Microscopy. A) The endocervical luminal surface showed an intact, cohesive 
epithelial cell layer (Mag. 2,000 X). B) In contrast, the ectocervical lumenal surface 
was covered with flattened and loosely attached epithelial cells (Mag. 200 X). 
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Figure 11: Visualization of Epithelial Junctions m the Human Endocervix and 
Ectocervix by Transmission Electron Microscopy. 
A) Endocervix showing classic tripartite junctions (arrows) typically found in simple 
columnar epithelia (Mag. 12,500 X). B) Higher magnification of endocervical 
adherens junctions (Mag 40,000 X). C) In the ectocervix, epithelial cells above the 
basement membrane are attached by robust adherens junctions (arrows). No 
discernable junctions were detected between epithelial (E) cells and an adjacent 
leukocyte (L) (Mag 5,000 X). D) Higher power of image C, arrows indicating 
adherens junctions (Mag 25,000 X). E) Apical ectocervical surface with no 
discernable junctions between loosely associated epithelial cells (Mag. 4,900X). F) 
Higher magnification of E showing possible remnants of epithelial junctions (arrows) 
(Mag 25,000 X). 
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Characterization of junctional molecules in human endocervical, ectocervical and vaginal 
epithelia by immunofluorescence 
Endocervix 
Immunofluorescence studies of the simple columnar epithelium of the endocervix 
revealed a similar distribution pattern for JAM-A and E-cadherin. Both were present at 
the contact between epithelial cells but not at the site of adhesion of epithelial cells to the 
basement membrane (Fig. 12a, b). The distribution of claudin-1 was irregular; a variable 
expression pattern was observed associated with progenitor epithelial cells proximal to 
the basement membrane (Fig. 12c). JAM-C was not detected in the endocervical 
epithelium (Fig. l2d). Z0-1 and occludin were localized between epithelial cells and also 
at the site of attachment to the basement membrane in some cells (Fig 12 e, f). JAM-A, 
occludin, Z0-1 , and claudin-1 were also observed in the endothelium of blood vessels 
(Fig. 12a, f, and data not shown) and Z0-1 was expressed by fibroblasts in the lamina 
I 
propria (Fig. 12e). Expression of E-cadherin and Z0-1 was visualized also in the 
epithelial layer lining endocervical glands (data not shown). Claudin-1 and occludin were 
also expressed, but to a lesser extent, along the basement membrane of endocervical 
glands (data not shown). 
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Figure 12. Junctional Molecules of the Endocervix, Visualized by 
Immunocytochemistry. All of the junctional molecules studied were detected in 
endocervical epithelial cell-cell junctions with the exception of JAM-C, a 
desmosomal component. Of interest, claudin-1 was also highly expressed in the 
basal stem cells and distribution was patchy throughout the endocervix. All 
images taken at 20x. 
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Ectocervix and Vagina 
No junctional molecules were detected in the apical layers of the ectocervical or 
vaginal epithelia (Fig. 13a-g). Tight junctional molecules were localized to the lower two 
thirds of the epithelium in a spiderweb-like pattern, indicative of their function in cell-cell 
adhesion (Fig. l3a-g). E-cadherin and JAM-A had a similar pattern of distribution, with 
expression brightest in the parabasal and basal layers (Fig 13a, b). JAM-A expression 
appeared to be decreased in the rapidly proliferating epithelial cells directly adjacent to 
the basement membrane. This was also true of junctional molecules claudin-1 and Z0-1 
(Fig 13c, e). Claudin-1 and JAM-C staining was most intense in the intermediate, 
parabasal and basal epithelium and also around dermal papillae. Staining for Z0-1 was 
less intense and localized to the parabasal and basal epithelium (Fig. 13e). Z0-1 
distribution was more punctate than the other junctional molecules studied and could also 
be visualized within the cytoplasm of the epithelial cells. This is in concordance with the 
known function of Z0-1 as an intracellular scaffolding molecule. Expression of occludin 
was diffuse and the intensity was highest in the parabasal epithelium (Fig 13f). As 
adhesion molecule expression patterns were identical in the ectocervical and vaginal 
epithelia, only images for the ectocervix are shown. 
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Figure 13: Junctional Molecules of the Ectocervix and Vagina Visualized by 
Immunocytochemistry. All junctional molecules studied were detected in both 
ectocervical and vaginal tissues, displaying a spider-web like pattern throughout 
the lower two thirds of the epithelium. No staining for tight or adherens 
junctional molecules was observed in the stratum corneum. 
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Permeability of Cervical Epithelia 
Cy3-labeled lgG was excluded by the tight junctions of the endocervical single 
cell columnar epithelium (Fig. 14a). In contrast, fluorescent Cy3-lgG penetrated the 
superficial layers of the ectocervical mucosal epithelium (Fig. 14b ). As noted above, 
these apical layers are composed of cornified epithelial cells that do not appear to have 
exclusionary epithelial adhesion junctions. Below these cells, about 3 or 4 cellular layers 
from the lumen, epithelial junctions restricted the diffusion of labeled IgG between 
epithelial cells. 
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Figure 14: Cervical Permeability to Cy3-labeled (red) IgG The endocervical epithelium 
provided a robust barrier to penetration of Cy3-tagged IgG, while the apical-most layers 
of the ectocervix were permeable. A) Endocervical tissue incubated with Cy3-labeled 
IgG. No diffusion is seen into the epithelium past the tight junctional complex. (Original 
Mag. 750x) B) Cy3-labelled IgG penetrated the apical cellular layers of ectocervical 
epithelium. (Original Mag. 600x) 
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Chapter 1 Discussion 
Cervicovaginal epithelial barrier integrity is maintained by intracellular junctions 
that prevent the invasion of microbes, with the exception of certain pathogenic organisms 
that have developed strategies to breach the epithelial barrier. Many other factors further 
fortify this barrier. Mucus produced by cervical and vaginal epithelial cells forms a 
glycocalyx on the epithelial surface that retains immunological mediators including 
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infiltrate into and through the epithelium to conduct immunosurveillance.40•78 The 
purpose ofthis study was to characterize cervical and vaginal epithelial junctions in order 
to better understand their role in STI pathogenesis and immune defense of the lower 
female genital tract. 
Our electron microscopy studies indicate that classical tight junctions comprise 
the principal intercellular junctions between epithelial cells in the endocervix, in 
accordance with the current knowledge of the structure of simple columnar epithelia. 182 
These tight junctions formed a barrier that was impermeable to Cy3-labeled-IgG. In 
contrast, the uppermost layers of the stratified squamous ectocervical epithelium were 
devoid of organized intracellular junctions, and the apical layers were permeable to Cy3-
labeled IgG. Exclusionary junctions were observed directly beneath this layer, and IgG 
did not penetrate beyond this point. 
Our study also surveyed the expression of junctional molecules representing the 
different types of intracellular junctions in both the columnar epithelium of the 
endocervix and the stratified squamous epithelium of the ectocervix and vagina. The 
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results from this investigation indicate that JAM-A, E-cadherin, occludin, claudin-1 and 
Z0-1 are abundant junctional molecules in the human endocervix. JAMC, a desmosomal 
junctional molecule, was not detected in the endocervix. Claudin-1 expression was found 
in distinct foci, whereas the other junctional molecules were expressed uniformly at sites 
of cellular contact throughout the epithelium. Previous studies of cervical cancer 
biomarkers have described select junctional proteins in human cervical tissue. E-cadherin 
was previously described in the endocervical mucosa183 and images published by Lee et 
al. depicted irregular punctuate claudin-1 staining localized to the basal cervical epithelial 
cells similar to that observed in the present study. 178 
All of the intercellular junctional proteins surveyed in this study including JAM-C 
were detected in ectocervical and vaginal stratified squamous epithelia. The ectocervix is 
structurally a part of the vaginal wall and shares a continuous, morphologically identical 
mucosal layer with vaginal tissue. 184 Therefore it is not unexpected that the distribution 
of JAM-A, JAMC, claudin-1, Z0-1 and E-cadherin was identical in these two tissues. 
Each of these molecules displayed a spiderweb-like distribution in the basal and supra-
basal layers consistent with their functions as mediators of cell-cell adhesion. There was 
little or no staining in the apical-most layers, where the epithelial cells gradually lose 
cell-cell contacts and are eventually sloughed into the lumen. Claudin-1, occludin, Z0-1 
and E-cadherin expression has been previously described in the human ectocervix.179•185 
Claudins 4 and 7 have been also detected in ectocervical and vaginal epithelial cells. 178 
JAM-A expression had not been reported in cervicaVvaginal epithelia, but it has been 
observed at other mucosal sites such as the intestinal and nasal epithelium.186•187 JAM-C 
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expression has not been well studied in stratified squamous epithelia and had not been 
detected previously in the female mucosal epithelium but had been observed in the 
endotheiium and retinal epithelium. 154' 188 The structure and distribution of adhesion 
molecules in the genital simple and stratified squamous epithelia is diagrammed in Figure 
15. 
Some pathogens are known to affect the integrity of epithelial junctions in order 
to facilitate transmission across the mucosal surface. In the context of the female 
reproductive tract, Nazli and coworkers showed that exposing female genital epithelial 
cells to free HIV virions or gp-120 envelope glycoprotein resulted in increased 
permeability. This correlated with increased production of the pro-inflammatory cytokine 
TNF-alpha and disruption of tight junctional molecules Z0-1 , occludin and claudins 1, 2, 
and 4.100 Of interest, many junctional molecules also serve as leukocyte adhesion 
receptors and so may play a role in the recruitment of CD4+ HIV target cells to the 
cervicovaginal lumen. JAM-A is a ligand of lymphocyte-associated antigen 1 (LF A -1) 
expressed on T cells, macrophages and neutrophils; it may provide a foothold for 
infiltrating leukocytes. 146' 189' 190 Similarly, E-cadherin is a receptor for the lymphocyte 
adhesion molecule alpha E beta 7 integrin on T cells. 147 
In contrast to tight and adherens junctions, there is little evidence that 
desmosomal structure is altered by pathogen invasion or inflammation.191 However, the 
desmosomal molecule JAM-Cis a known ligand for the macrophage- I (Mac-1) receptor 
on macrophages and neutrophils, and JAM-C regulates the influx of leukocytes, 
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leukocyte to migrate between epithelial cells, the epithelial junctional bonds must be 
disrupted. Permeability to infiltrating leukocytes is largely regulated by secreted pro-
. f] k" d h k" 88 192 m ammatory cyto mes an c emo mes. ' 
A definitive understanding of the composition of cervical and vaginal epithelial 
junctions also provides an important foundation for future studies on pathogen 
transmission. For infections such as HIV, preventing epithelial barrier breach by cell-free 
or cell-associated virus is of the utmost importance.9 Results from our study indicate that 
the uppermost layers of the stratified squamous epithelium covering the vagina and 
ectocervix may not comprise a physical barrier to STI invasion but a potential zone for 
interactions with immunological mediators which can penetrate and may be retained at 
this site. Mapping the normal expression of key molecular regulators of barrier resistance 
is an important first step to elucidating how microbes take advantage of these 
mechanisms to infect a host. 
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A. Human Endocervix B. Human Ectocervix and Vagina 
Occludin 
JAM ..A 
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Figure 15: Localization of Selected Adhesion Molecules in Female Genital Epithelia. 
A) The endocervical epithelium contains classic tripartite junctions. The tight junctions 
are located near the apical surface and are responsible for sealing the epithelium, as 
well as for maintaining cellular polarity. Adherens junctions are located directly below 
the tight junctions, and are primarily responsible for maintaining cell-to-cell adhesion. 
E-cadherin is the common transcellular component of all epithelial adherens junctions 
and is anchored to the actin cytoskeleton by vinculin and alpha and beta catenins. 
Desmosomes are the most basal adhesion structure and endow the tissue with 
mechanical resistance and strength. The major extracellular components of the 
desmosome are desmoglein and desmocollin, which connect to intermediate filaments 
of adjacent cells through an intracellular scaffolding network. B) The most robust 
junctions in the stratified squamous epithelium of the ectocervix and vagina lie in the 
parabasal epithelium, just above the basal layer in contact with the basement 
membrane. Adherens junctions are particularly abundant. The integrity of the junctions 
progressively lessens as epithelial cells are pushed toward the apical surface, where 
they become cornified, lose all cellular contacts, and are sloughed into the lumen. 
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Chapter 2: An in-vitro Model for Cell-Associated HIV Transmission Across the 
Human Vaginal Mucosa 
Chapter 2 Introduction 
Genital secretions from HIV-infected men and women can contain high numbers 
of HIV -infected leukocytes, and as such cell-associated HIV may play an important role 
in transmission.9 Yet, the vast majority of in vitro studies that investigate HIV 
transmission use free virus as the infectious dose. The preference for cell-associated or 
cell-free transmission has important implications for vaccine and microbicide 
development because strategies that target cell-free HIV may not be effective against 
cell-associated HIV, and visa versa. A prime example is the widespread interest in the 
broadly neutralizing antibody VRCOI, which is effective in blocking cell-free HIV 
transmission but has been shown to be less successful against cell-to-cell transmission. 193 
For these reasons, we set out to establish a robust and reproducible model for CA-HIV 
transmission. 
As previously discussed, HIV transmission rates are significantly enhanced by C. 
trachomatis, N gonorrhoeae, herpes simplex virus (HSV) infections, bacterial vaginosis 
(BY) and other inflammatory states in the vaginal mucosa. 13 Mechanisms that attract and 
assist in the migration of immune cells from the blood to the inflamed mucosa (basal to 
apical infiltration), such as chemokine secretion and increased leukocyte adhesion 
molecule expression are classic features of epithelial inflammation. It is also conceivable 
that inflammation in the vaginal mucosa can facilitate infiltration of foreign (transmitter) 
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leukocytes, specifically HIV infected seminal leukocytes, from the vaginal lumen into the 
epithelium (apical to basal infiltration). The increased presence of both seminal HIV+ 
leukocytes and CD4+ susceptible host cells in the inflamed epithelium would create an 
environment that favors transmission, especially since cytokines such as TNFa, IL-l a , 
IL-lP and IL-6 that activate NF-KB activity are known to enhance local viral 
replication. 194 As such, it is our hypothesis that cervicovaginal inflammation enhances 
cell-associated HIV transmission. 
Inflammation may also compromise epithelial barrier function. TNF alpha is a 
prominent proinflammatory cytokine produced during genital inflammation that has been 
h . 1 b.,. 100 149 195---198 s own to mcrease mucosa permea 1 tty. ' ' Although its effect on the 
permeability of stratified epithelia is unclear, TNFa is found in the cervicovaginallavage 
fluid (CVL) of women with genital inflammation and vaginal explant cultures infected 
with C. albicans and N gonorrhea secrete TNFa into the surrounding culture medium. 
Recent studies by Nazli et al. showed that inflammation-induced barrier permeability was 
restored by inhibiting TNFa in uterine epithelial monolayers. 100 
Although genital inflammation is a known risk factor for HIV acquisition 13, few 
models exist to study CA-HIV penetration through inflamed epithelia. Here we propose 
the use ofEpiVaginal tissue as better model for CA-HIV transmission in both normal and 
inflammatory states. 
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Chapter 2 Results 
EpiVaginal Cultures Resemble Human Vaginal Mucosa 
EpiVaginal cultures are composed of primary vaginal epithelial cells and 
fibroblasts that form highly differentiated, stratified tissues that closely resemble human 
vaginal epithelium (Fig. 16). As epithelial barrier function is regulated by the integrity of 
tight and adherens junctions, it was important to assess whether the distribution of 
epithelial junctions was similar between normal vaginal mucosa and the EpiVaginal 
model. Immunofluorescence localization of junctional molecules in EpiVaginal tissue 
cultures was similar but not identical to that of human ectocervical and vaginal 
epithelium (Fig. 16). The intermediate, suprabasal and basal layers of both epithelia are 
characterized by the expression of tight junctional molecules zona occludins 1 (Z0-1 ), 
junctional adhesion molecule A (JAM-A) and claudin-1 as well as adherens junctional 
molecule epithelial cadherin (E-cadherin). No staining for junctional molecules was 
observed in the SC, as the upper layers of the epithelium lack robust cell-cell junctions.77 
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Figure 16: Epithelial Adhesion Molecule Expression in Normal Ectocervical Tissue 
and EpiVaginal Cultures. Expression of epithelial tight junctional molecules (JAM-
A, claudin-1 and Z0-1) as well as adherens junctional molecule E-cadherin were 
assessed under normal conditions. The nuclei are labeled with DAPI (blue) and the 
adhesion molecule of interest with Cy3 (red). Images taken at 20x, n=3. 
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The Stratum Corneum as an Immunologic Battlefront 
A recent publication from our laboratory demonstrated that the stratum corneum 
of ectocervical explant tissue is permeable to Cy3-tagged lgG.77 To visualize the 
permeability of the apical epithelial layers of the EpiVaginal tissue, both virus-sized ( 100 
nm) and leukocyte sized (10 f.!m) fluorescent polystyrene beads were added to the 
epithelial surface and allowed to diffuse into the tissue for 2 hours. Bead penetration into 
the tissue was tracked by confocal microscopy. In Figure 17a-b, confocal Z-stacks were 
merged to create three dimensional renderings of bead diffusion into the EpiVaginal 
tissue. The stratum corneum retained both sizes of fluorescent beads and diffusion was 
rarely seen past 90flm (Fig. 17 a-b). In contrast, U937 monocytoid cells and primary 
MDMs added to the apical surface ofEpiVaginal tissue cultures readily infiltrate the 
loose stratum corneum, adhering to sloughing epithelial cells and inserting psdeupodia 
between them (Fig. 17c-e). Although the diffusion of similarly sized (10 f.!m beads) was 
not observed at depths below 120flm (Fig. 17b ), a small number of cells were capable of 
infiltration to depths >200flm, indicating that the macrophages actively infiltrated 
through an otherwise intact barrier. 
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Scanning Electron Microscopy: Credit: Dr. JeffPudney 
Figure 17: EpiVaginal Permeability to Fluorescent Microspheres and Leukocytes. 
10 flm and 100nm labeled microspheres (Molecular Probes), PMA-activated U937 
leukocytes or MDMs were added to the apical surface of EpiVaginal cultures to 
assess tissue permeability. Confocal microscopy was used to take Z-stack images. 
Representative 3D rendering of A) 100 nm (virus sized) bead penetration, B) 10flm 
(macrophage sized) bead penetration and C) U937 cells. Scanning electron images 
of D) U93 7 leukocyte and E) MDM migrating within the top layers of the stratum 
corneum. 
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A Model for Ectocervical and Vaginal Inflammation 
In order to induce genital inflammation, EpiVaginal tissue cultures were treated 
apically with 50J.1l of recombinant TNFa (1 OJ.lg /mL) for 24 hours. We observed 
significantly increased secretion of proinflammatory cytokines and chemokines IL-6, IL-
8 and RANTES upon exposure to TNFa (Table 7). Noteworthy, IL-6 and IL-8 are present 
in the cervicovaginallavage (CVL) fluid of women with genital inflammation195-197 and 
RANTES was of particular interest as it has been shown to be a potent chemokine and 
inhibitor ofHIV transmission. 199 Stimulation with TNFa also induced the upregulation of 
epithelial-expressed ICAM-1, an important leukocyte adhesion molecule that has been 
studied by others as a potential biomarker for vaginal inflammation.200 ICAM-1 was 
visualized in the lower third of the epithelium by immunofluorescence. (Fig 19 a-b) 
TNFa Does Not Induce Permeability by Classical Measurements 
Studies with epithelial monolayers have shown a great reduction in transepithelial 
electrical resistance (TEER) after exposure to TNFa, 100 but here we report a moderate 
and insignificant decrease in this stratified tissue model (Table 7). No significant cell 
death or cytotoxicity was observed as measured by MTT viability assay (Table 7) and 
TUNEL staining (data not shown). As an additional measure of permeability, 0.02% 
sodium fluorescein was added to the apical tissue surface and basolateral dye leakage was 
measured at 30min. As noted in Table 6, there was no significant difference in 
permeability between the control and TNFa -treated cultures. 
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Cytokine/Chemokine Secretion by EpiVaginal™ Cultures 
medium (p~/mL) lOJ1~/mL TNFa (p~/mL) fold increase 
IL-6 73.7 (±19.97) 259.8 (±142.44) 3.5*** 
IL-8 42,182.58 (±29,404) 142,201.4 (±39,171) 3.4*** 
RANTES 184.1 (±227.48) 1,652.2 (±1,810.5) 9.0* 
EpiVaginalTM Culture Viability 
1% Triton X 
Control 10J1~/mL TNFa (%control) (%control) 
TEER 100% 78% (±27.4) NA 
MIT 100% 76% (±23.8) 23.6% (±15.6)* 
dye leakage 0% 14% 319.7% (±1.53)** 
Table 7: Characterization of the Epivaginal Inflammation Model. Treating the 
EpiVaginal cultures with 50f.Ll of lOf.Lg/mL TNF alpha for 24 hours stimulates 
EpiVaginal cultures to significantly increase secretion of proinflammatory cytokines 
and chemokines IL-6, IL-8 and RANTES into the basolateral supernatant. TNFa did 
not cause significant epithelial cytotoxicity or permeability as measured by 
transepithelial electrical resistance (TEER), sodium fluoroscene leakage or MTT 
viability assay. 1% Triton X, a permeabilizing agent, was used as a negative control. 
(Mann Whitney U test) N=S-6 , 3 separate experiments. N=6, 3 separate experiments 
Statistical analysis performed with Mann Whitney U test. P values <0.05* , <0.01 **, 
<0.001 *** 
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Junctional Rearrangement in the EpiVaginal Inflammation Model 
TNFa.-induced inflammation increases barrier permeability through the 
f . . 1 1 1 . h 1 . h 1' 100149198 b . . rearrangement o JUncttona mo ecu es m ot er mucosa eptt e ta · · ut It ts 
unknown if the stratified epithelium of the lower female reproductive tract responds to 
this cytokine in a similar manner. To determine the effects of TNFa. on junctional 
molecule expression in the vaginal epithelium, EpiVaginal tissues were exposed to 
lOflg/mL TNFa. for 24 hours. There was a slight disruption in E-cadherin expression and 
a very noticeable reduction in the expression of alpha catenin, an intracellular scaffolding 
molecule for the adherens junction. (Figure 18, c-f) The loss of alpha catenin did not 
correspond to an increase in permeability (Table 7 ) or a change in the distribution of 
tight junctional molecules JAM-A, Z0-1 and claudin-1 in EpiVaginal tissue as visualized 
by immunofluorescence (data not shown). Preliminary microarrays showed no difference 
in the transcription of the aforementioned junctional molecules between normal and 
inflamed EpiVaginal cultures. However, there was a robust upregulation in the 
transcription of matrix metalloproteinases (MMPs) 1, 3, 9, 10 and 13 which may 
contribute to increased epithelial permeability to leukocytes without inducing an overall 
disruption in epithelial junctional structure. (Appendix A) 
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I-CAM-I alpha catenin E-cadherin 
control 
TNFa 
Figure 18: Altered Expression of Jllilctional Molecules in the EpiVaginal 
Inflammation Model. ICAM-1 is normally expressed only by the epithelial cells in 
the basement membrane and exposure to TNFu resulted in increased ICAM-1 
expression in the lower third of the epithelium. Inflammation resulted in the loss of 
alpha catenin but not E-cadherin from the adherens jWlction. Taken at 60x. 
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TNFa Increases Epithelial Permeability to Infiltrating Leukocytes, but not to Virus-sized 
Particles or Leukocyte-sized Beads 
While TNFa does not induce permeability as measured by TEER and 
permeability dye leakage, it was important to determine if the upper layers of the 
inflamed epithelium were more permeable to particles and leukocytes. To this end, both 
virion-sized (1 OOnm) and macrophage-sized (1 OJ..lm) fluorescently labeled polystyrene 
beads were used to assess inflammatory barrier function. In Figure 19 a-b, confocal Z-
stacks were merged to create three dimensional renderings of bead diffusion into the 
EpiVaginal tissue. The SC retained both virus and cell-sized beads but TNF-induced 
inflammation did not increase barrier permeability. 
To assess the ability of TNF-treated EpiVaginal cultures to exclude foreign 
leukocytes, PMA-activated U937 macrophages were added to the apical surface of 
EpiVaginal tissue for 30min, 2 and 4 hours before fixation and the infiltrating leukocytes 
were tracked by confocal microscopy. While there was no statistical difference in the 
number or depth of infiltrating cells at 30 minutes, there were significantly more U937 
leukocytes infiltrating into TNF-treated EpiVaginal cultures at 2 and 4 hours than into 
non-inflamed controls (Figure 19 c-e). Both control and inflamed EpiVaginal cultures 
were capable of excluding 10J..lm cell-sized beads (Fig. 18 b, 19a-b), indicating that the 
epithelial barrier remained intact. 
99 
A. IOOnm beads 
10000000000 ,.--------------------1 
1000000000 
1: § 100000000 
u. 
0:: 
10000000 
1000000 
0-30um 31-60um 61 -90um 91- 121-
120um 150um 
B. IOum beads 
1000,------------------------------------l 
N 
E 100 
E 
U; 
"D 
.. 1l 10 
Dmedium 
• TNF treated 
151- 181-
180um 210um 
Dmedium 
•lNF treated 
0-30um 31-SOum 61-90um 91-120um 121-150um 151-1 80um 181-210um 
100 
30m in 
c. 
o control 
1000.---------------------------------~ 
• TNF treated 
0-30um 31-60um 61-90um 91-120um 121-150um 151-180um 181-210um 
D. 2 hours 
o control 
1000 
• TNF treated 
E 100 
E 
~ 
ii 10 u 
G-30um 31-60um 61-90um 91-120um 121-150um 151-180um 181-210um 
4 hours 
E. 
o control 
1000 
• TNF treated 
N 
E 100 
E ]! 
Qi 10 0 
0-30um 31-QOum 61-90um 91-120um 121-150um 151-180um 181-210um 
101 
Figure 19: Infiltration Kinetics of U937 Macrophages. lOf.!m and lOOnm labeled 
microspheres (Molecular Probes) and PMA-activated U937 leukocytes were 
labeled with a green Jive ceH stain (CMFDA) and added to the apical surface of 
EpiVaginal cultures. Confocal microscopy was used to take Z-stack images, which 
were then rendered into 3D images using Zen 2009 software. Quantification of cell 
counts and density of fluorescence were performed using ImageJ. A) 1 OOnm bead 
and B) 10f.!m bead diffusion in TNFa treated cultures. PMA-activated U937 
macrophages were labeled with green live cell tracker (CMFDA) and added to the 
apical surface of control and TNFa-treated EpiVaginal tissue. Leukocyte migration 
was tracked by confocal microscopy and quantified using ImageJ at 30min, 2 and 4 
hours. Average ceH counts and standard error is shown. C) At 30min, there was no 
statistical difference between control and TNF -treated tissues but at D) 2 hours and 
E) 4 hours, macrophages migrated significantly deeper into EpiVaginal tissue than 
non-inflamed control tissues. Statistical analysis performed using Mann Whitney U 
test. N=5-6, 3 separate experiments. P values <0.05*, <0.01 **, <0.001 *** 
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Apical to Basal Infiltration ofHIV -infected Primary Blood Derived Macrophages 
Genital inflammation is a known risk factor for HIV acquisition.13 In order to 
model macrophage infiltration in the context of a vaginal exposure to CA-HIV, we 
assessed the infiltration of three different MDM populations into TNFa treated 
EpiVaginal tissue. Three groups of MDM populations were counted; donor-matched 
uninfected controls ('Unexposed'), MDMs that were exposed to HIV ('Exposed') and a 
subset of the Exposed MDMs that became productively infected with HN ('GFP 
positive' ). All MDMs were dual-labeled with a red live cell stain (CMPTX, Invitrogen) 
and added to the apical tissue surface. After 2 hours, HIV -infected macrophages could be 
visualized within the stratum corneum (0-90~m) as well as in the intermediate and 
suprabasal epithelial layers (90-150~m) of inflamed EpiVaginal tissue (Fig 20a-c ). There 
was no consistent difference in the number ofMDMs in the stratum corneum between the 
HIV Exposed and Unexposed groups, although we did see significant donor-to-donor 
variability in this regard. In our system, the number of GFP+ (HIV infected) 
macrophages at depths >90~m was significantly higher than the pool of cells added to the 
epithelial surface (Fig 20e) although there was significant donor to donor variability (Fig 
20a-c). It is important to note that a small number ofGFP+ (HIV+) cells were detected at 
depths > 15 0 ~m . Infected macrophages were also observed to infiltrate ectocerv ical 
explants but due to the limited availability of fresh surgical tissue, it was not possible to 
perform enough replicates for statistical analysis (Fig 20f). 
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Figure 20: Apical to Basal Migration of IDV -infected MD Ms. MDMs were infected 
with an R5-t~opic, GFP-expressing HIV construct 3 days prior to the experiment. At 
that time, 2-3% ofMDM's added to the surface ofTNF-treated EpiVaginal cultures 
expressed GFP as visualized at 1 Ox. Leukocytes were co-stained with a red live cell 
stain (CMPTX). Three groups of MDM populations were counted; donor-matched 
uninfected controls ('Unexposed'), MDMs that were exposed to IDV ('Exposed') 
and a subset of the Exposed MDMs that became productively infected with HIV 
('GFP positive'). A-C) Infiltration of MDMs from three different donors that were 
Unexposed to IDV, Exposed to HIV or GFP+ (HIV+). D) Predicted GFP positive 
versus real GFP positive cell counts. Predicted values were calculated based on the 
assumption that in the absence of a migratory advantage or disadvantage, the 
predicted number of GFP positive cells deep in the epithelium should also represent 
the same percentage of cells added to the apical surface. E) Representative 3D 
rendering of 2 hour infiltration of GFP+ positive HIV infected MDMs into 
EpiVaginal tissue. F) Representative 30 rendering showing 2 hour infiltration of 
MDMs infected with an mCherry expressing mv construct (dual labeled with a live 
cell green cell tracker (CMFDA)) into ectocervical explant tissue. Statistical analysis 
performed using Wilcoxin Signed Rank Test. P values <0.05*, <0.01 **, <0.001 *** 
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Chapter 2 Discussion 
The mucosal epithelium functions to provide a physical barrier between the 
outside environment and the body, excluding large particles but allowing the movement 
of water and some small ions. While the intermediate, suprabasal and basal epithelial 
layers form exclusive tight and adherens junctions, previous work by our lab has 
demonstrated that the stratum corneum is permeable and retains labeled immunoglobulins 
(Figure 14). Studies by others have shown that lOOnm beads and free virions can be 
trapped by the surface of both endocervical and ectocervical explant tissue,64•20 1 as well 
as in the SC of simian vaginal epithelia. 64 This suggests that the SC could potentially 
facilitate the direct contact of pathogens and immune components.77 In vivo, this may be 
a mechanism by which both virions and HN infected Trojan Horse leukocytes diffuse 
into the inflamed vaginal epithelium, bringing them in closer proximity to host target 
cells. This hypothesis is further supported by the studies here that have shown that beads 
and foreign leukocytes are similarly retained in the stratum corneum. 
TNFa induces various degrees of barrier dysfunction in intestinal, lung and nasal 
mucosa.93•96•95 As reported here, treatment with proinflammatory cytokine TNFu did not 
induce a significant increase in permeability as measured by TEER or sodium fluorescein 
leakage, the standard assays used by many for measuring barrier function in epithelial 
monolayers. The integrity of the lamina propria and the basal epithelial layers in the 
stratified mucosa may have overshadowed any minute changes in permeability resulting 
from TNFa exposure, and as such monitoring the diffusion of microbeads was 
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particularly informative. Penetration of lOOnm and lOJ..Lm beads indicated no increase in 
permeability of the SC or intermediate layer after TNF treatment. 
Inflammatory mediators, particularly TNFa, have been described to cause barrier 
dysfunction through the rearrangement of junctional molecules. The majority of these 
studies were performed using epithelial monolayers and as such it was important to 
describe any inflammation induced changes in junctional molecule expression in the 
stratified cervicovaginal mucosa. No changes in the distribution of tight junctional 
molecules JAM-A, claudin-1 and Z0-1 were visualized by fluorescence microscopy. 
However, there was a significant TNFa-induced reduction in alpha catenin at the 
adherens junction with some concordant alterations in E-cadherin. By preliminary 
microarray analysis, there were no evident changes in the transcription of alpha catenin 
(unpublished data) indicating that alterations in alpha catenin expression may be 
regulated by other mechanisms. Of great interest, others have reported that alpha catenin 
may have a role in leukocyte migration.202 Endothelial cell-cell contacts are regulated by 
the VE-cadherin complex, and in a recent study, leukocytes were prevented from exiting 
the vasculature in response to inflammatory stimuli by prevention of alpha catenin 
dissociation from the VE-cadherin complex?02 Alpha catenin expression has also been 
reported to be decreased in the inflamed lung epithelium of asthmatic patients, and it was 
proposed that this enhances leukocyte migration and creates a more permeable epithelial 
barrier.160 The authors of this study were unable to determine the fate of the disassociated 
alpha catenin, although they hypothesized it was not due to enzymatic cleavage as other 
junctional molecules appeared to be unaffected. It should be noted that another study 
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found that chemically inhibiting the alpha catenin association with endothelial junction 
enhanced, not prevented, leukocyte migration.202 The above fmdings have led many to 
hypothesize that alpha catenin is not merely an adherens junction scaffolding molecule, 
but rather that it may regulate actin dynamics and cell-cell adhesion on a complex 
signaling leve1.159,202,203 In our model, the loss of alpha catenin did not appear to induce 
barrier dysfunction as evident by TEER measurements, sodium fluorescein leakage, 
staining for other junctional molecules and microbead diffusion. More studies need to be 
performed to assess how the loss of alpha catenin affects epithelial barrier function and 
leukocyte infiltration into the stratified squamous mucosa. 
As visualized by scanning electron and confocal microscopy, both primary and 
cell-line derived leukocytes adhere to and infiltrate within the SC. Although the 
intermediate, parabasal and basal layers of the vaginal epithelium were impermeable to 
inert macrophage-sized particles before and after TNF-induced inflammation, TNFa 
significantly increased the inward infiltration of foreign, HIV harboring leukocytes deep 
into the epithelium. Furthermore, lllV -infected MDMs penetrated deeper into the 
epithelium compared to free virus-sized beads in both control and inflammatory 
conditions, indicating that CA-IDV may have better access than free virus to target CD4+ 
leukocytes in the vaginal epithelium. 
Additionally, the infiltration of HIV infected macrophages (as assessed by GFP 
expression) were significantly enhanced over the exposed and uninfected donor controls. 
If HIV infected macrophages infiltrate the vaginal epithelium at an enhanced rate over 
non-infected MDMs in vivo, this may enhance male to female CA-HIV transmission. 
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Others have reported that HIV -infected macrophages are more migratory than non-
infected controls. There are several potential mechanisms by which HIV infection may 
enhance macrophage infiltration. Others have shown that infected macrophages secrete 
more MMPs and one of the primary purposes of MMP secretion by macro phages is the 
breakdown of extracellular matrix proteins and junctional molecules to enhance 
leukocyte infiltration. In addition, HIV infection may alter CCR5 expression and 
therefore chemotaxis to RANTES. 
We also wanted to assess if exposed but uninfected MDMs infiltrate differently 
than macrophages that have not been exposed to the virus. This analysis was performed 
to determine if exposure to gpl20 or pro-inflammatory molecules produced by 
productively infected MDMs in culture affected the infiltration of exposed MD Ms. It was 
also possible that some of the 'Exposed' MDMs were productively infected, but that GFP 
was not detected by low power (lOx) microscopy. Although there was a significant 
difference in the infiltration of unexposed and exposed MDMs in two donors, the trend 
was inconsistent. 
While more studies are needed to define the molecular events that enable 
enhanced infiltration, we hypothesize that the secretion of chemokines such as RANTES 
and the enhanced expression of leukocyte adhesion molecules such as ICAM -1 by 
inflamed vaginal epithelial cells play a role. After CA-HIV crosses the epithelial barrier, 
the presence of TNFa in the female genital tract may further enhance HIV transmission 
to host target cells and local viral replication. Infection of epidermal and vaginal explant 
tissues with N gonorrhoeae and C. albicans can result in TNFa production and enhanced 
llO 
Langerhans cell mediated infection ofT cells.92 TNFa signaling and subsequent NF-KB 
activation of resident leukocytes has been well documented to induce HIV transcription 
d . 1 1. . 194 an vtra rep tcatwn. 
A growing body of research supports cell-associated HIV as an important mode of 
transmission across the female genital tract. For example, Salle et al. have published 
findings similar to those presented here on cell-associated SIV transmission in macaques. 
As early as 21 hours after vaginal exposure to SIV leukocytes, labeled donor cells were 
found disseminated throughout the vaginal mucosa, iliac and sacral lymph nodes. The 
innoculum used is comparable to what would be found in the semen of some HIV-
infected men.74 Zacharopoulos et al. have shown that labeled PBMC's infiltrate into 
intact, non-inflamed murine vaginal epithelium within 4 hours.73 In another murine 
model, the enhanced permeability of inflamed genital epithelium mounted in a dual 
chamber system resulted in increased transmigration of HIV and infection of target T 
cells beneath the epithelium.204 While the simian and murine reproductive epithelia are 
not perfect models for the human female mucosa, the complementary findings of these 
studies with the one presented here provides some insight into the mechanisms of cell-
associated HIV transmission and how it is influenced by inflammation. 
Mechanistic studies of HIV transmission across human, stratified genital mucosa 
have been previously limited by the availability and reproducibility of explant tissue. As 
presented here, the use of the EpiVaginal tissue model allowed a detailed study of the 
apical to basal infiltration of leukocytes across normal and inflamed epithelia. In the past, 
HIV transmission was studied mainly in the context of cell-free virus. Recent and 
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compelling research suggests that cell-associated transmission is not only possible, but 
that it is an important mechanism by which HIV is able to infect a new host. It is our 
hope that our model can be used to further define molecular mechanisms ·of CA-HIV 
transmission to inform the future development of compounds to prevent HIV 
transmission. 
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Conclusions 
30-40% of all HIV infections occur through the female genital mucosa.205 Some 
of these infections can be attributed to breaks in the epithelium, as would occur with 
ulcerating STis or microabrasions incurred during intercourse. Animal and explant 
models show that HIV transmission likely occurs through intact mucosa as well, a 
h b _.. .1. db · 1 . fl . 9741301 69201 Alh h process t at may e 1.aC1 1tate y gemta m ammation. ' ' ' ' t oug concurrent 
infection with an STI greatly increases the likelihood of HIV infection, few have 
undertaken the challenge of modeling HIV transmission in an inflammatory environment. 
Most investigators model HIV transmission using supra-physiologic concentrations of 
free virus, and further ignore the potential role of cell-associated HIV in the 
establishment of infection.9 The studies presented here were performed out of the need 
for a better understanding of CA HIV transmission as well as HIV transmission in an 
inflammatory environment. It is our hypothesis that inflammatory processes that lead to 
increased expression of leukocyte adhesion molecules and chemokines, play an important 
role in increased susceptibility to CA-HIV. 
Inflammation-induced rearrangement of junctional molecules is known to 
correlate with increased epithelial permeability.92•94' 149'186 As such, it is important to 
ascertain which junctional molecules are expressed in the ectocervical and vaginal 
epithelium as well as to understand how these structures respond in health and disease 
states. Previous to our studies, there was no comprehensive study of the junctional 
molecules that are expressed in the cervicovaginal epithelium. In 2011 , we reported that 
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claudin-1, JAM-A, JAM-C, occludin, Z0-1 and E-cadherin were all highly expressed in 
the stratified epithelium of the lower genital mucosa (Figure 13).77 As evidenced by 
fluorescence microscopy, these junctional molecules are localized to epithelial cell-cell 
contacts, form a spider web-like pattern in the lower two thirds of the epithelium, and are 
most strongly expressed near the basement membrane (Figure 13). There was no staining 
for junctional molecules in the stratum corneum, an area devoid of junctions as was also 
evidenced by transmission electron microscopy. Junctional molecule localization in 
normal human vaginal and ectocervical epithelium resembles that of the EpiV aginal 
tissue model (Figure 16), which is a stratified tissue reconstruction made from primary 
vaginal epithelial cells. However, it should be noted that there were some minor 
differences in junctional molecule localization, which may be largely related to tissue 
thickness and plane of section. Using this model, we were able to determine that pro-
inflammatory stimuli (TNF alpha) did not change the distribution of tight junctional 
molecules, as occurs in other mucosal layers, with the exception of a possible and minor 
disruption in E-cadherin expression at the junction. However, TNF treatment did induce a 
rather striking loss of alpha catenin from the adherens junction (Figure 18). It is unclear 
how the dissociation of alpha catenin from the junction affected epithelial integrity; while 
the intermediate, suprabasal and basal layers of TNF -treated EpiV aginal tissues remained 
impermeable to fluorescent beads and permeability dyes (Table 7 and Figure 17), the 
epithelium was considerably more permissive to leukocytes. Others have reported that 
alpha catenin expression was altered in the inflamed lung epithelium of asthmatic 
patients, and it was proposed that this enhanced leukocyte migration and created a more 
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permeable epithelial barrier. 160 The authors of that study did not speculate what caused 
the decrease in alpha catenin at the epithelial junction, such as degradation or 
relocalization. Others have reported that alpha catenin can be found in the nucleus where 
it can modulate beta catenin signaling and transcription, promoting cell-to-cell 
adhesion.206 Alternatively, alpha catenin localization to the cytoplasm is associated with 
decreased epithelial cell-to-cell adhesion and in the case of carcinogenesis, increased 
epithelial migration and metastasis.207 There was no histological evidence of alpha 
catenin in the cytoplasm or nucleus, although more sensitive detection methods such as 
Western blot and/or immunoprecipitation of alpha catenin could be performed in the 
future to definitively rule this out. Ubiquitin-independent proteasomal degradation of 
alpha catenin has been shown to be mediated by its association with armadillo repeat 
containing 8 alpha (ARMeS alpha) in a yeast 2 hybrid screen, but the significance of this 
is unclear.208 Alpha catenin may also have a role in inflammatory signaling; genetic 
ablation in the murine epidermis results in an inflammatory phenotype and NF-KB 
activation?09 The above findings have led many to hypothesize that alpha catenin is not 
merely an adherens junction scaffolding molecule, but rather may regulate actin 
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Potential Mechanisms ofEnhanced HIV-infected MDM Infiltration 
In Chapter 2, we reported that more HIV infected (GFP+) MDMs infiltrate the 
inflamed EpiVaginal tissue than exposed but uninfected donor controls (Figure 20). More 
studies are needed to defme the mechanisms that contribute to HIV -augmented 
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infiltration. There are several leukocyte-specific factors that could play a role in HIV-
enhanced infiltration, including alterations in chemokine receptor expression, 
macrophage secretion of proteases such as MMPs, and enhanced macrophage expression 
of adhesion molecules such as LF A-1 and/or Mac-1. 
The predominant chemokine in the TNF-treated EpiVaginal model is RANTES, a 
potent macrophage chemoattractant (Chapter 2). RANTES binds and signals through the 
CCR5 receptor on macrophages, which as previously mentioned is also an HIV co-
receptor. Of interest, HIV infection in several cell types, including macrophages, results 
in a decrease in surface expression of CCR5 as well as CD4 and CXCR4?10-214 This 
feature common is to other viruses as it is thought to prevent superinfection of the cell 
and subsequent toxicity, thus enhancing viral replication.210'211 '215 Decreased surface 
expression of CCR5 is mediated by the viral protein Nef through enhanced receptor 
internalization from the surface and degradation.210 This would likely impair the ability 
of macrophages to migrate to epithelial-secreted RANTES, and indeed it has been 
hypothesized that this may inhibit macrophage chemotaxis in vivo?15 In addition, HIV 
infection can stimulate macrophage production of TNF alpha and RANTES, which can 
also downregulate surface CCR5 expression?16 The macrophages in these experiments 
were potentially exposed to macrophage-derived cytokines in culture and additionally 
exposed to recombinant TNF alpha and epithelial-produced RANTES for 2 hours after 
being added to the EpiVaginal tissue. However, the role of Nef, TNF alpha and/or 
RANTES in downregulating CCR5 surface expression may be in part mitigated by the 
actions of the HIV viral protein Tat, which has been shown to upregulate CCR5 
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expression213 , induce enhanced migratory behavior2 17 and activation2 18 in monocytes. 
Further experiments need to be conducted to quantify levels of CCR5 expression on 
MDMs at the time they are added to the EpiVaginal tissue surface to determine the 
significance of these findings in our system. 
Macrophages use MMPs to degrade extracellular matrix and epithelial junctional 
proteins to facilitate transmigration. MMP secretion is tightly regulated and is usually 
induced during inflammation. 132'219 HIV -infected MDMs have altered profiles of MMP 
secretion, and specifically have been shown to increase the secretion ofMMP-1 , -2, -7,-
9, and -12 in vitro. In vivo, aberrant MMP production in HIV infected patients has been 
associated with the development of several HIV -related diseases including HIV-
associated neurological disease (HAND), gingival deterioration and AIDS-related 
cancers.Z19 HIV infection has been shown to skew macrophage populations towards an 
inflammatory phenotype in vitro220'221 , and increased MMP secretion may be downstream 
of these pro-inflammatory signaling events.Z19 In agreement with this hypothesis is the 
report that viral Tat upregulates MMP-9 secretion by monocytes through enhancement of 
NF-KB signaling.Z22 Although zymography would be required to confirm this in our 
system, increased MMP secretion by HIV -infected macrophages may contribute to 
increased infiltration into inflamed EpiVaginal tissue, and it is additionally possible that 
this mechanism can overcome any potential inhibition of chemotaxis to RANTES. 
Macrophage-expressed integrin adhesion molecules LFA-1 (CD1la/CD18) and 
Mac-1 (CDllb/CD18) are well described to facilitate macrophage migration through 
epithelial tissues. 145 There are several reports of altered expression of these adhesion 
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expression has been demonstrated to be upregulated on MDMs, and the authors of this 
study postulated that this many correlate with increased endothelial adhesion and 
subsequent spread of HIV to distal tissues.223 Additionally, another group found that 
increased CD 11 a and CD 11 b levels on blood monocytes from infected patients correlated 
with decreased CD4 surface receptor expression.224 Tat, but not Nef, has been shown to 
enhance T cell and macrophage adhesion to the endothelium which may have a role in 
AIDS-related vasculopathy.225 One group found that the addition of extracellular Tat 
mimicked many of the altered adhesion and migration profiles of HIV -infected 
monocytes, suggesting a major role for Tat in this context.218 Like the enhanced 
production ofMMPs by HIV-infected monocytes, increased monocyte adhesion has been 
attributed to Tat induction of IL-lP and TNF-a secretion.218 In the future, it would be 
interesting to characterize the surface expression of leukocyte adhesion molecules on the 
surface of the infected MDMs used in this assay to better understand if this contributes to 
increased adhesion, and if so, to then characterize the molecular mechanisms that alter 
macrophage adhesion. 
The Immunologic Battlefront 
We and others have demonstrated that the stratum corneum of the vagina and 
ectocervix retains large molecules, beads, leukocytes and virus-sized particles leading us 
to hypothesize that this region may constitute an 'immunological battlefront', or the place 
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where microbes and immune defenses meet. It is unclear whether this mechanism would 
facilitate or hinder HIV transmission. On one hand, trapping virions in an area rich in 
innate antimicrobial compounds (SLPI, lysozyme, lactoferrin, defensins and 
cathelicidins) as well as anti-HIV antibodies (found in highly exposed women and/or the 
semen oftransmitter) may increase the likelihood of virus inactivation. Here we have also 
shown that free virus sized particles (lOOnm) diffuse into and are held in the SC of 
EpiVaginal cultures, which is concordant with other studies.64 Leukocytes, as well as 
leukocyte sized beads (1 OJ.lm) are also retained in the SC. Unlike the inert beads, non-
infected and infected leukocytes were capable of infiltrating beyond the SC into the 
epithelium reaching depths of>200J.1m within 2 hours. In vivo, the trapping ability of the 
SC is further enhanced by the endocervix-derived gel-forming mucus.61 •80 It remains 
unclear if this is mechanism by which infectious material is sequestered away from the 
vulnerable epithelial cells beneath the SC, or one that provides a foothold for infectious 
material to gain access to host CD4+ target cells. 
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Figure 21: The Immunologic Battlefront. The stratum corneum of the vaginal and 
ectocervical epithelium lacks robust cell-cell junctions and as demonstrated here, 
retains large molecular weight immunological mediators, virus-sized fluorescent 
beads, and leukocytes. As such, the SC could constitute an 'Immunologic 
Battlefront' , or the place where microbes and the immune defense meet. It is unclear 
whether the trapping ability of the SC facilitates or impedes HIV transmission. 
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TNF alpha Induced Barrier Dysfunction 
Much of what we know about inflammation-induced epithelial barrier 
permeability is based on inflammatory bowel disease (IBD).226-228 Many groups have 
demonstrated that inflammatory mediators, particularly TNFa and IFN gamma, alter tight 
junctional function through a variety of mechanisms including vesicular internalization of 
junctional molecules, degradation of junctional molecules, phosphorylation, and 
cytoskeletal rearrangement.229 While this has yielded a great quantity of information 
describing the dynamics of epithelial junctions in response to inflammatory stimuli, it is 
unknown if the epithelium in the female genital tract behaves in a similar fashion. There 
are some major differences between the intestinal and ectocervical/ vaginal epithelium. 
Most notably, the latter is a stratified layer; this means that the metabolically active 
vaginal epithelial cells found in the intermediate, parabasal and basal epithelial layers are 
shielded by the SC from inflammatory mediators, antigens, etc. in the vaginal lumen. It 
has been previously proposed that in vitro vaginal epithelial monolayers may be hyper-
reactive to inflammatory stimuli for this reason. 103 In contrast, intestinal epithelial cells 
are normally exposed to lumenal antigens and may be programmed to respond differently 
to inflammatory stimuli. 
Ablation of intestinal epithelial barrier function, characterized by the inability to 
exclude lumenal contents, is characteristic of IBD and Crohns Disease,95,146,227- 229 but is 
not generally observed in even extreme cases of vaginal and ectocervical inflammation 
(barring the presence of open wounds). However, a few studies have reported 
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inflammation-induced impaired barrier dysfunction in the female genital epithelium. 
Nazli et al. have shown that gpl20 induces TNFa secretion from uterine epithelial cell 
monolayers and that this increased epithelial permeability. Nonoxynol-9 (N-9), an early 
microbicide candidate, was retrospectively shown to disrupt the vaginal epithelium in 
mouse models, as well as in the human rectal epithelium?04'230 It is thought that this may 
be part of the mechanism by which N-9 enhances HIV transmission. Another failed 
microbicide candidate, cellulose sulfate, similarly causes inflammation, epithelial barrier 
permeability and may increase HIV transmission with repeated use.204'231- 233 Preclinical 
safety studies are not typically performed using human, stratified vaginal tissue and 
instead rely primarily on epithelial cell monolayers and rodent models, in addition to 
limited primate studies. In the past, this has meant that many candidate microbicides 
advanced to clinical trials, where they were found to not meet acceptable safety 
standards.9,103,164'204,230,231 The EpiVaginal model could help to fill the need for a 
reproducible and more physiologically relevant model for microbicide testing.113'114 
Microbicide Development 
Currently, there are no microbicides for HIV prevention approved for clinical use. 
The relative success of ARV prophylaxis created a band wagon effect, and as a result the 
microbicide formulations currently in clinical trials almost unilaterally utilize tenofovir, 
dapivirine, maraviroc and FTC to block HIV transmission. Although ARV containing 
formulations have received much press, as discussed in Section 7, the study findings have 
been mixed. Three trials reported that tenofovir pre-exposure prophylaxis resulted in a 
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44%-75% decrease in transmission in both heterosexual and homosexual individuals, but 
other trials have failed to show efficacy. 166 Furthermore, the production cost and delivery 
will be a significant barrier to getting an ARV-based microbicide to the populations most 
in need. As of the December 2011 WHO Report, 56% of HIV patients in sub-Saharan 
that need ARVs are receiving them and drug coverage in the rest of the developing world 
ranges from about 15% in North Africa and the Middle East to 68% in the Caribbean and 
Latin America? Undoubtedly, it will be a considerable challenge to scale up production 
and delivery systems to meet the current demand in addition to covering HIV negative, at 
risk individuals. 
Other agents that can block HIV transmission, such as antibodies and CCR5 
antagonists, are also viable microbicide candidates. Broadly neutralizing HIV antibodies 
have been highly sought for both vaccine and microbicide studies, and thus far more than 
a dozen have been identified (Fig 22)?34.235 Neutralizing anti-HIV antibodies produced 
by HIV-infected individuals are hard to come by; although most HIV infected individuals 
make antibodies against Env glycoproteins within a few months of initial infection, long 
term studies have shown that the high rate of viral mutation, especially in Env variable 
regions, is constantly driving HIV escape from antibody recognition.236-238 Env is the 
only membrane-expressed HIV protein and as such is the most immunogenic viral 
protein.234 A handful of antibodies that are capable of neutralizing >80% of HIV strains 
have been isolated from rare patients that produce neutralizing antibodies and these 
promising candidates are being pursued with great interest (Fig 22).234 Broadly-
neutralizing antibodies are attractive microbicide candidates because they can be directed 
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against both cell-free as well as cell-associated HIV viral epitopes. The broadly 
neutralizing antibody VRC01 , which is very effective in blocking cell-free HIV 
transmission, has been shown to be less successful against cell-cell transmission 193 and 
the binding of neutralizing antibody 4E10 is much more effective after gp120-CD4 
engagement exposes gp41, as would occur in cell-cell HIV transfer.239'240 Recent studies 
have shown that VRC01 as well as an antibody cocktail consisting ofb12, 2F5, 4El0 and 
2G 12, formulated as a vaginal gels effectively blocked cell-free HIV transmission in 
humanized mice.241 The antibodies b12 and VRC01 have also been shown to be effective 
in preventing HIV transmission by intravaginal challenge in macaques.241•242 These 
antibodies are also being pursued as both conventional and passive vaccine candidates. 
VRCO 1 is being readied for a clinical trial in African newborns which is drawing some 
criticism from the scientific community as antibodies are generally expensive and labor 
intensive to produce.243 However, there is much hope in new Nicotiana-derived 
antibodies, which can be inexpensively and rapidly produced.244.245 
There has also been much interest in generating compounds that compete with 
HIV for CCR5 binding regions, similarly to human chemokines RANTES and MIP 1 
alpha and beta?36238238-242 Maraviroc, an ARV currently used to treat HIV patients, works 
via this mechanism and is currently being pursued as a microbicide candidate?46,247 There 
are an increasing number of both ARV-based and CCR5 blocking studies that utilize 
alternative microbicide delivery methods, such as Lactobacillus-expressed CCR5 
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based delivery mechanisms do not require daily application; this could be of considerable 
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benefit to the field especially since a major problem that has plagued microbicide trials, 
regardless of the drug investigated, has been patient adherence. The recently failed 
VOICE trial reported that only 28% of study participants in the oral tenofovir prophylaxis 
had detectable serum plasma levels at their quarterly visits. 167 Although there was no 
significant protection amongst the women who did take the drug, or use the vaginal gel, 
this brings to light a significant issue. It was suggested in the VOICE trial report, as well 
as by many others, that longer-lasting microbicide options might be a more effective 
f . 167 means o prevention. 
We postulate that the EpiVaginal model could be a useful tool in determining the 
efficacy of microbicide formulations. For example, it could be useful in defming 
epithelial-microbicide interactions and resultant toxicity. 113' 114 Adding microbicides to 
the EpiVaginal surface could also provide information about the efficacy of microbicide 
candidates in the presence of vaginal epithelial-derived host factors such as anti-
microbial molecules. However, there are several drawbacks to the EpiVaginal tissue 
model. It may not accurately simulate the interactions between the microbicide and 
mucus that would occur in vivo, as the secreted mucus on the normal human vaginal 
epithelial surface is derived from the endocervix. The lack of this protective mucus layer 
may also result in enhanced STI and HIV transmission in this in vitro model. Although 
EpiVaginal cells do express membrane-associated mucins Muc-1 and -4, the addition of 
autologous endocervix-derived mucus may be an improvement that could be made to this 
system. Another drawback of the EpiVaginal tissue model is the lack of a leukocytic 
immune response to inflammatory stimuli and pathogens, as would occur in vivo. In our 
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laboratory, this is particularly pronounced when the EpiVaginal is infected with HSV-2, 
which in the absence of the full spectrum of the mucosal immune system, results in the 
complete destruction of the epithelium within 24 hours (unpublished data). It is currently 
possible to seed the EpiVaginal tissue with Langerhans cells and it may be possible in the 
future to create an EpiVaginal tissue that also contains T cells and macrophages, as well 
as other immune cells. The ability to model CA-HIV transmission in an inflammatory 
environment in the EpiVaginal model may be a useful tool to test microbicide safety and 
efficacy in the future especially when used in conjunction with other modeling systems. 
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Adapted from: Koff and Berkley N Engl J Med 201 0; 363 :e7 
Figure 22: Neutralizing anti-HIV Antibodies Target Key Env Regions. Env 
glycoproteins gp120 and gp41 are the only surface expressed HIV viral proteins, 
and as such are the target of most anti-HIV antibodies. The images above depict a 
few key regions targeted by the most effective broadly neutralizing .antibodies 
including the CD4 binding site, exposed sugar residues (glycan shield), variable 
loops (Vl-V2, V3) as well as the membrane proximal exposed region (MPER) of 
gp41. 
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HIV Transmission Is Not Reduced Through Trials Designed to Treat Sexually 
Transmitted Infections. Why? 
By all accounts, genital inflammation and co-infection with sexually transmitted 
pathogens greatly enhance susceptibility to HIV. Mathematical modeling estimates that 
in 1990, 39% of all HIV infections in South Africa were attributable to co-infection with 
an STI.15 If this is true, then why does it seem that STI treatment programs introduced in 
the 1990's did not significantly curb the HIV epidemic? The studies are conflicting; 
although a 1995 randomized control trial in Tanzania reported a 40% decrease250 in HIV 
incidence in communities where STI treatment programs were enhanced, many other 
trials have shown that STI treatment has no impact at all on HIV prevalence?51- 253 
If genital inflammation enhances HIV transmission, then why have STI treatment 
programs been ineffective at reducing the rate of new HIV infections? Firstly, all STI 
treatment is not equal. In the absence of equipment and trained staff in developing 
countries, STI identification is based on syndromic criteria, i.e vaginal discharge and 
other symptoms. A recent study of at-risk women visiting local South African STI clinics 
found that shocking 87.5% of patients were incorrectly diagnosed using syndromic 
criteria and received inappropriate therapy.196 Not surprisingly, the authors found that 
increased risk of HIV infection was only associated with laboratory-diagnosed STis, not 
the presence of discharge. It is also possible that early STI treatment, especially in areas 
where HIV prevalence is very high, was simply too little too late. It has been 
hypothesized that STI transmission plays a larger role in the initial establishment of an 
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HIV epidemic in a new region, when the number of infected persons and relative risk of 
HIV . I 252 exposure to ts ow. 
In · addition, the current methods for measuring and detecting vaginal 
inflammation are limited. Colposcopic examination detects overt signs of inflammation 
(redness, lesions) as well as the presence of some STis, which can be accurately 
confirmed by laboratory testing. Like colposcopy, screening CVL fluid for pro-
inflammatory cytokines (IL-l beta, IL-6, IL-8, etc.) is a standard for assessing the safety 
of candidate microbicides. However, baseline cytokine concentrations in the CVL can be 
highly variable and subject to variability based on the detection method.254 It is quite 
possible that low level inflammation may influence HIV transmission, but that the current 
standard methods of detection are not sensitive enough to detect sub-clinical 
inflammation. Many of the aforementioned trials that have studied the correlation 
between STI treatment programs and HIV infection use a positive/negative STI 
laboratory test as their primary criteria.14'87'250'251 '255'256 However, it is unknown how long 
low level inflammation may persist after clearance of infection. Bacterial vaginosis as 
well as vaginal practices such as douching, washing, and use of irritating chemical agents 
are common amongst Africans; 11 '257 these also cause inflammation, and could likely 
enhance HIV transmission in the absence of concurrent infection with another STI. 11 
The lack of correlation between STI treatment programs and decreased HIV 
infection rates in past studies was unexpected, but informative. These results suggest that 
the mechanism by which genital inflammation enhances HIV infection is not dependent 
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on active STI infection. Rather, it leads us to believe that the inflammatory factors that 
enhance HIV transmission persist after clearance of infection. 
Future Directions 
There is much information to be gained from the history of microbicide trials that 
can be used to inform the future generation of topical compounds to prevent HIV 
transmission. Several microbicide candidates that have proven to be effective in vitro 
and/or in animal models have failed in clinical trials. This is problematic not only 
because clinical trials are costly, but because repeat failures may lead to a lack of 
confidence in and less support for future trials. 
The evidence for inflammation-enhanced HIV transmission is overwhelming yet 
very few study HIV transmission in this context. A successful microbicide will have to be 
effective and safe in women with STis, BV and other forms of genital inflammation. It 
has been long assumed that enhanced HIV infection in women with genital inflammation 
is caused by the increased presence of mucosal target cells and NF-KB activated viral 
transcription. Unfortunately, this has meant that other potential mechanisms of 
inflammation-enhanced HIV transmission, such as increased barrier permeability and 
enhanced CA-HIV transmission have been understudied. In addition, the vast majority of 
investigators use high titer, purified free virus as a means to mimic the HIV transmission 
event. This is not physiologic; real world HIV transmission occurs in the presence of CA-
HIV, free virions, and semen. As such, the role of infected seminal leukocytes and 
semen in male to female HIV transmission is still unclear. 
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We have developed and characterized an EpiVaginal inflammation model to 
better understand the relationship between inflammation and IllY transmission in the 
lower female reproductive tract. Here, we show that TNFa-induced inflammation does 
not result in increased vaginal epithelial permeability to dyes or beads, but that it does 
enhance the apical to basal infiltration of both non-infected and HIV -infected primary 
macrophages. We have identified several features of vaginal inflammation, including the 
increased expression of RANTES, ICAM -1, and the likely increased secretion of matrix 
metalloproteinases, all of which function to facilitate leukocyte migration in vivo. In the 
future, strategies that inhibit leukocyte infiltration through blocking chemokine signaling 
or leukocyte binding to adhesion molecules may be a viable HIV prevention strategy. 
Future studies on HIV transmission mechanisms using the EpiVaginal model could 
include live or killed pathogens (infection/inflammation model) and/or Langerhans cells 
and other IllY target leukocytes to better model the vaginal mucosal microenvironment. 
These variations of the EpiVaginal model could be valuable additions to current 
preclinical testing systems to assess the safety and efficacy of microbicide candidates 
under a variety of conditions. 
There are more than 34 million people currently infected with HIV, and in many 
parts of the developing world, women are disproportionately affected. These women, 
who are all too often unable to negotiate condom usage or are victims of sexual violence, 
are in desperate need of a method of HIV prevention that can be used with or without 
their partner's knowledge. An effective microbicide could be the key to stemming the 
HIV epidemic and it is our hope that the data presented here can be used in the 
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development of a safe, effective means for these women to protect themselves against 
infection. 
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APPENDICES 
Appendix A: Microarray Studies 
In order to gain a complete understanding of how inflammation effects the 
EpiVaginal tissue, both full thickness (epithelial cells and fibroblasts, FT-VEC 1 00) and 
partial thickness (epithelial cells alone, PT-VEC 1 00) tissues were exposed to either 
TNFa or poly (I:C), a TLR3 agonist, for 24 hours. The treatment groups were all 24 
hours in duration and were as follows: FT-VEC 100 treated with 50~-tl medium alone, FT-
VEC100 treated with 50~-tl of 10~-tg/mL TNFa, FT-VEC treated with 50~-tl of 25~-tg/mL 
poly (I:C), partial thickness (PT-VEC100) treated with 50~-tl medium alone, PT-VEC100 
treated with 50~-tl of 10~-tg/mL TNFa and PT-VEC treated with 50~-tl of 25~-tg/mL poly 
(I:C). The data from TNFa treated cultures are presented here. For each treatment group, 
3 separate EpiVaginal cultures were homogenized in Trizol and the samples were sent to 
the Boston University Microarray Core for mRNA extraction and microarray analysis 
utilizing Affmetrix Genechip Human Gene 1.0 ST arrays. Analysis was performed with 
the assistance of the BU Microarray Core Facility. Differential expression of genes was 
considered significant if the log2 transformation value was greater than 1, or a 2 fold 
change in mRNA expression. 
Of the 19,608 genes assayed, the transcription of 364 genes was altered in the full 
thickness EpiVaginal TNFa inflammation model (Table 8). Figure 23 depicts graphic 
comparisons between the transcription of some key molecules of interest in full thickness 
(epithelial cells and fibroblasts) and partial thickness (epithelial cells only) in response to 
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TNFa treatment. In many cases, it is clear that some inflammatory gene products are 
made in the epithelium, others in the fibroblasts, and some equally in both tissues. It is 
also possible that fibroblast signaling molecules induced a transcriptional response in the 
epithelial cells and visa versa. We were able to confirm the TNFa -induced upregulation 
of ICAM-1, RANTES, IL-8 and IL-6 that was previously observed (Chapter 2) in 
addition to identifying some new markers of inflammation in this model. Transcription of 
T cell chemoattractants CXCL 9, I 0 and II and CCL20 was markedly induced, with 
lesser effects on CCLI and CX3CLI. Although the latter two chemokines also induce 
monocyte chemotaxis, there was an overall lack of macrophage chemoattractants MIP 1 
alpha and beta (CCL 3 and 4) (Fig. 24a). The only strongly upregulated macrophage 
chemokine was RANTES (CCR5), which leads us to hypothesize that this molecule may 
have an important role in apical to basal infiltration in this inflammation model. 
We have also identified a number of pro-inflammatory cytokines in addition to 
IL-8 and IL-6 that are upregulated in the presence of TNF a, including IL-beta, IL-17C, 
GM-CSF (CSF2), M-CSF (CFSl), and TNFa itself. Like IL-6, IL-lp has an important 
role in the acute inflammatory response and signals through NF-KB, and as such can 
activate HIV replication. GM-CSF (granulocyte-macrophage colony stimulating factor) 
and M-CSF (macrophage colony stimulating factor) have important roles in monocyte/ 
macrophage differentiation and surviva1.88 M-CSF has additional roles in promoting a 
pro-inflammatory phenotype in macrophages and has been known to induce cytoskeletal 
rearrangement, enhanced adhesion and migration. IL-17C is known to function in innate 
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immunity of the intestinal epithelium, and acts synergistically with TNFa and IL-
l ~-258,259 
Matrix metalloproteinases have a crucial role in inflammation and in promoting 
leukocyte migration. In the EpiVaginal model, TNFa induced the transcription of 
MMP13, and to a lesser extent MMPs 1, 3, 9, 10 and 13. As is depicted in Figure 24, 
MMPs are produced as inactive zymogens that become active after cleavage by activating 
molecules.260 There was a modest change in the transcription of some of these activating 
molecules, including plasminogen activator (PLAT), plasminogen activator urokinase 
(PLAU) and plasminogen activator urokinase receptor (PLAUR). 
Of interest, there was no discemable change in the transcription of any junctional 
adhesion molecules we studied (including alpha catenin). ICAM-1 was the only 
leukocyte adhesion receptor that was upregulated by TNF-induced inflammation, 
indicating that the loss of alpha catenin from the epithelial junction is regulated by other 
mechanisms. 
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CDR1 1 .1 CYLD 1 .0 .A.C.A.T1 -1.0 TOMtv140 -1.2 MYC -1 .7 
CGNL1 "1.1 MIRLET7F1 "1.0 C.A6 -1 .0 L.A.PTM48 -1.2 R.A.ET1 E -1.9 
GR810 1.1 V'ITAP 1 .0 FAHD28 -1.0 HEG1 -1.2 TEX28 l --2:2 
UGT1 .A9 '1.1 PTPN2 1.0 THBD -1 .0 I<I.A.A.1143 -1 .2 
F'OMZP3 1 . 1 ITGB6 1 (I SLC3584 -1.0 I<I.A.A.1144 -1.2 
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Table 8: Significant Variations in Gene Expression in TNF-induced 
Inflammation in Full-Thickness (FT) EpiVaginal Tissue. There were 300+ genes 
· differentially expressed between 1NFa-treated and control EpiVaginal tissues. 
Differential expression of genes was considered significant if the log2 
transformation value was greater than 1, or a 2 fold change in mRNA expression. 
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c. 
D. 
Microarray Data: 1NF-induced MMP Transcription 
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Figure 23: TNFa-induced Inflammation Comparison: Full and Partial Thickness 
EpiVaginal Tissues. Fold change over medium-treated control in the transcription 
of A) cytokines B) chemokines C) matrix metalloprotineases and D) junctional 
adhesion molecules. 
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Adapted from: Overall and Lopez-Otin. Nature Reviews Cancer 2, 657-672 
(September 2002) 
Figure 24: MMP Activation Cascade. MMPs are created as inactive zymogens 
(proMMPs). Enzymatically active MMPs are generated through a proteolytic cascade 
that involves plasminogen cleavage by urokinase to create plasmin, which then cleaves 
proMMPs to create active MMPs. Active MMPs can cleave other proMMPs as well as 
junctional adhesion molecules, extracellular matrix components, cytokines and 
chemokines. There was a modest change in the transcription of some of these 
activating molecules, including plasminogen activator (PLAT), plasminogen activator 
urokinase (PLAU) and plasminogen activator urokinase receptor (PLAUR). 
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Appendix B: Lymphocyte Infiltrations 
Although seminal macrophages are the more likely vectors of CA-HN 
transmission (Section 4.2), infected CD4+ T cells are also present in seminal fluid and 
may similarly contribute to transmission. As was noted in Chapter 2 and Appendix A, 
TNF-treated EpiVaginal epithelial cells produce chemokines that attract T cells and the 
other inflammatory processes described here (JAM-A and E-cadherin expression, 
increased ICAM-1 expression, potential increase in MMP activity) would also enhance 
the infiltration activity ofT cells. As such, we performed a few preliminary experiments 
to assess the infiltration oflymphocytes isolated from whole peripheral blood. 
In two experiments, 2 x I 0"'6 and 5 x 1 0"'6 unactivated T cells were labeled with a 
live cell stain (CMFDA), added to the apical surface ofEpiVaginal tissue and tracked by 
confocal microscopy. Unactivated T cells appear to infiltrate similarly to MOM and 
U937 macrophages, and in these experiments, perhaps a little further into the epithelium 
(Fig 25 a, b). However, it should be noted that there were more lymphocytes added to the 
apical tissue surface in this experiment in comparison to the macrophage infiltration 
assays in Chapter 2, and the increased numbers ofT cells deep in the epithelium may be a 
reflection of this. In this experiment there was also not a significant enhancement in 
infiltration seen with TNFa treatment. This may be due to a lack of responsiveness in 
unstimulated T cells to chemokines produced by inflamed EpiVaginal cultures. It has 
been shown that unstimulated T cells isolated from PBMCs are unresponsive to RANTES 
and IL-8261 and have very low surface expression of CXCR3, the receptor for chemokines 
CXCL9, 10 and 11 .262 However, activation with IL-2 and PHA increases CXCR3 
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. d h h . h h k" 261262 In b . fil . expresston an t us c emotaxts to t ese c emo mes. ' a su sequent m 1 tratton 
experiment, PHA and IL-2 stimulated T cells showed a trend towards increased apical to 
basal infiltration, although this was not statistically significant. (Fig 25c) 
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Figure 25: Apical to Basal Migration of Primary T cells. A) 2xl OA6 and B) 5xl 0/\6 
unstimulated T cells were isolated from whole peripheral blood and added to the 
apical surface of both of control and TNF -treated EpiVaginal tissue. Migration at 2 
hours was assessed by confocal microscopy. A more robust infiltration was observed 
in A) in comparison to B), but in both groups there was no difference in migration 
between medium and TNF-treated cultures. n=2. C) T cells were stimulated for 2 
days with ll..-2 and PHA prior to migration assay. Activated T cells may show 
enhanced migration in TNF -treated cultures, but in this single experiment, the trend 
was not significant. n=3 
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Appendix C: ICAM-1 Blocking Studies 
The data presented in Chapter 2 and Appendix A suggests that ICAM-1 
expression, which is highly upregulated in TNF-treated EpiVaginal cultures, may have a 
role in enhanced macrophage infiltration into inflamed epithelium. In a study by Chancey 
et al., the use ofLactobacillus-expressed, anti-ICAM-1 variable chain antibody fragments 
(Fabs) blocked cell-associated HIV transmission across a cervical epithelial 
monolayer.263 In this study, they also found that CA-HIV was transmitted more 
effectively than cell-free virus, and monocyte-associated virus was transmitted most 
efficiently?63 ICAM-1 is expressed in the epithelial cells next to the basement membrane 
in vivo and in normal EpiVaginal tissue cultures, extending into the parabasal and 
intermediate layers in TNF -treated tissue cultures. Since ICAM -1 is not expressed by 
sloughing cells in the SC, it is not directly exposed to the apically added leukocytes. 
However, macrophages that reach the intermediate layer may be able to access epithelial-
expressed ICAM-1. To test the potential role of ICAM-1 in apical to basal leukocyte 
infiltration through stratified epithelia, we added a polyclonal anti-ICAM-1 antibody 
(50Jlg/mL in 50JlL, R&D systems) to the epithelial surface 1 hour prior to the addition to 
leukocytes. As evident in Figure 26a and b, the ICAM-1 antibody consistently blocked 
the TNF-induced increase in both U937 and MDM infiltration. 
In order to assess whether the anti-ICAM-I antibody blocking was specific, a 
series of experiments was performed in which control non-specific sheep IgG, was run in 
parallel. In these experiments, while an anti-ICAM-1 antibody consistently blocked 
MDM infiltration, non-specific IgG appeared to have a partial blocking effect, suggesting 
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that the mechanism ofthe anti-ICAM-1 blocking antibody is in part non-specific. We are 
currently conducting experiments with a monoclonal ICAM-1 antibody, and are 
considering the use ofFabs in future experiments. 
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Figure 26: ICAM-1 Blocking Studies. 1 x 1 Q/'6 PMA activated U93 7s or 
MDMs and were isolated from whole peripheral blood, cultured for 7-10days 
and added to the apical surface of both of TNF -treated EpiVaginal tissue. 
Migration at 2 hours was assessed by confocal microscopy. A) Activated U937 
macrophages and B) MDM migration into the EpiVaginal tissue pre-treated 
with an anti-ICAM-1 blocking antibody. C) 1 x 10/\6 MDMs were added to the 
apical tissue surface, which has pre-incubated with anti-ICAM-1 antibody or 
non-specific lgG for 1hr. 
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